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BRET bioluminescence resonance energy transfer 
cAMP cyclic 3’‑5’ adenosine monophosphate 
CB1 cannabinoid 1 receptor 
CB2 cannabinoid 2 receptor 
DBC 
1‑bisdeoxycoelenterazine, di‑dehydrocoelenterazine, 
Coelenterazine 400a, DeepBlueCTM 
pEC50 negative logarithm of half‑maximal response concentration 
Emax maximal ligand‑induced response 
ESI‑TOF electrospray ionization time‑of‑flight mass spectrometry  
GPCRs G protein‑coupled receptors 
hCB1 human CB1 receptor 
hCB2 human CB2 receptor 
HRMS high‑resolution mass spectra 
mCB2 mouse CB2 receptor 
NBD 4‑nitro‑1,2,3‑benzoxadiazole fluorophore 
THC Δ9‑THC, (-)‑trans‑∆9‑tetrahydrocannabinol 
TLC thin‑layer chromatography 
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Cannabinoid CB1 and CB2 receptors are members of the G protein‑coupled receptor family, 
which is the largest class of membrane proteins in the human genome. As part of the 
endocannabinoid system, they have many regulatory functions in the human body. Their 
malfunction therefore triggers a diverse set of undesired conditions, such as pain,  neuropathy, 
nephropathy, pruritus, osteoporosis, cachexia and Alzheimer’s disease. Although drugs 
targeting the system exist, the molecular and functional mechanisms involved are still poorly 
understood, preventing the development of better therapeutics with fewer undesired effects. 
One path toward the development of better and safer medicines targeting cannabinoid 
receptors relies on the ability of some compounds to activate a subset of pathways engaged 
by the receptor while sparing or even inhibiting the others, a phenomenon known as biased 
signaling. To take advantage of this phenomenon for drug development, a better profiling of 
the pathways engaged by the receptors is required. Using a BRET-based signaling detection 
platform, we systematically analyzed the primary signaling cascades activated by CB1 and 
CB2 receptors, including 9 G protein and 2 β‑arrestin subtypes. Given that biased signaling is 
driven by ligand‑specific distinct active conformations of the receptor, establishing a link 
between the signaling profiles elicited by different drugs and their chemotypes may help 
designing compounds that selectively activate beneficial pathways while avoiding those 
leading to undesired effects. We screened a selection of 35 structurally diverse ligands, 
including endocannabinoids, phytocannabinoids and synthetic compounds structurally similar 
or significantly different from natural cannabinoids. Our data show that biased signaling is a 
prominent feature of the cannabinoid receptor system and that, as predicted, ligands with 
different chemotypes have distinct signaling profiles. The study therefore allows for better 
understanding of cannabinoid receptors signaling and provides the information about tool 
compounds that can now be used to link signaling pathways to biological outcomes, aiding 
the design of improved therapeutics.  
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G protein‑coupled receptors (GPCRs) transduce external signals to intracellular responses 
upon activation by ligands such as small molecules, hormones, neurotransmitters, 
chemokines, and photons1. Ligand binding on the extracellular side of the transmembrane 
receptor results in conformational rearrangements in the transmembrane domain2, leading to 
the recruitment and activation of G proteins3,4, phosphorylation by G protein‑coupled receptor 
kinases (GRKs), interaction with arrestins and eventually receptor desensitization and 
internalization, recycling or degradation5,6. The type of G protein activated by the receptor 
determines which intracellular signaling cascades are triggered, regulating downstream 
physiological responses. While some GPCRs activate only one or a few G proteins, others 
interact with several members of multiple G protein subfamilies, as well as multiple β‑arrestin 
subtypes7–9. Once engaged by the receptors, the β‑arrestins can also lead to intracellular 
responses10. 
The human endocannabinoid system consists of cannabinoid CB1 and CB2 receptors, along 
with additional receptors, endocannabinoids and enzymes involved in their transport and 
metabolism11. CB2 regulates immune responses and inflammatory pathways. While being 
expressed mostly in cells of the immune system with the highest expression in B‑lymphocytes, 
it is also found in the peripheral nervous system12. In contrast, CB1 is one of the most abundant 
GPCRs in the brain13, where it regulates neurotransmitter release from presynaptic neurons 
and is responsible for synaptic plasticity and psychoactive responses associated with 
marijuana consumption14. 
The endocannabinoid system is involved in neuromodulatory activity, cardiovascular tone, 
energy metabolism, bone formation, immunity, and reproduction, whereas its malfunction 
triggers various inflammatory conditions resulting in atherosclerosis15, neuropathy16, 
nephropathy, pruritus, osteoporosis17, Alzheimer’s disease18, autoimmune diseases19 and 
cancer20. It is reported that both cannabinoid receptors and endogenous ligands are 
upregulated in tumor tissue compared with non‑tumor tissue, where CB2 has a strong 
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anti‑inflammatory effect and plays an important role in cell homeostasis21. Therefore, the 
spectrum of physiological activities makes the endocannabinoid system a promising target for 
treatment of various diseases. Cannabinoid receptors in spinal chord are targeted for 
neuropathic pain22, while cannabinoid inverse agonists are used as appetite suppressors to 
treat obesity23. 
Both receptors were reported to couple mainly to Gi/o proteins, modulating intracellular 
signaling pathways, such as inhibition of cAMP‑production, activation of extracellular receptor 
kinases (ERKs) and G protein‑coupled inward rectifying K+‑channels (GIRKs), and to recruit 
and activate β‑arrestins24–27. In addition, there is evidence for activation of members of other 
G protein families under certain conditions28–30, receptor dimerisation31, internalized26,32, and 
recycling30. 
Despite the fact that phytocannabinoids have been in use for millennia, the molecular basis of 
their pleiotropic actions is still not well understood. A major hurdle for effective treatment with 
natural products is the lack of selectivity of known natural cannabinoids and 
endocannabinoids. It belongs to the peculiarities of natural cannabinoid receptor ligands, 
which are mainly agonists, that they exist in high numbers as endocannabinoids, as well as 
phytocannabinoids, while none of them seems to be specific for one single cannabinoid 
receptor. Due to the high homology between the ligand binding domains, they activate both 
CB1 and CB2 as well as some additional receptors, such as GPR55, TRPV1 channels and 5-
HT3 receptors. The pleiotropy of the cannabinoid system extends to their signaling cascade 
as it has been reported that CB1 and CB2 can engage members of different G protein families 
and that some ligands seem to show biased activity toward these different effectors30,33–40. The 
structural diversity of naturally occurring cannabinoids thus makes them an ideal playground 
to unravel their specific signaling pathways and to search for artificial ligands with specific 
properties, both in receptor activation/inactivation and biases in signaling. As positive effects 
are likely achieved exclusively through the regulation of one of the receptors and may even 
be associated with a specific signaling pathway, this approach may lead to better 
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pharmacological understanding and therapy. For instance, CB2 selective compounds would 
allow targeting of CB2‑mediated pathologies without the undesired  psychoactive effects 
mainly resulting form the co‑activation of the neuronally expressed CB1 receptors. Achieving 
such selectivity is a major hurdle for the development of CB2-targeting drugs. Similarly, a 
better mapping of the signaling pathways that can be triggered by different subclass of 
cannabinoid ligands could help linking specific pathways to beneficial or adverse biological 
outcomes.  
The ability of certain ligands to preferentially activate subsets of the signaling pathways over 
others engaged by a given receptor, which is know as biased signaling or functional 
selectivity9,41,42, is pervasive within the family of GPCRs and generated hope for the 
development of better and safer drugs43. Yet, the lack of tool compounds allowing for linking 
specific pathways to desired therapeutic responses, combined with the lack of knowledge 
concerning the nature of the ligand–receptor interactions that drive biases, has hampered the 
development of functionally selective drugs demonstrating clinical advantages. Given that  
signaling bias is believed to result from ligand‑specific distinct active conformations of the 
receptor44–50, profiling the signaling of ligands with distinct chemotypes should inform us on 
the relationship between chemical structures and receptor responses, in addition to provide 
tool compounds to directly test the impact of specific biases on biological functions. Here we 
assessed the CB1/CB2 selectivity and signaling profile of structurally diverse ligands, 
including endocannabinoids, phytocannabinoids and synthetic compounds structurally similar 
or significantly different from natural cannabinoids. 
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Selecting structurally diverse library of CB ligands 
The 35 cannabinoid receptor ligands we selected for this study originate from several 
structurally diverse chemotypes (Table S1). SR144528, AM630, AM1241, WIN55912-2 and 
CP55940 are well characterized synthetic cannabinoid ligands38,51. SR144528 and AM630 are 
CB2 inverse agonists, AM1241 is a CB2 agonist, whereas WIN55912-2 and CP55940 are 
mixed CB1 and CB2 agonists. Δ9-THC (henceforth referred to as THC), cannabinol, HU210, 
nabilone, HU308 and JWH133 are phytocannabinoid‑derived CB modulators38,51,52. THC, 
cannabinol, HU210 and nabilone have been described as mixed CB1/CB2 agonists, while 
HU308 and JWH133 are CB2-selective agonists. The endogenous cannabinoid ligands 
2‑arachidonoyl glycerol (2-AG) and anandamide, both non-selective activators of CB1 and 
CB238,51, were also included in the screening library. A more recently discovered CB2 selective 
triazolopyrimdine-based scaffold is also represented in the screening set by RO6435559, 
RO684439553, RO686909454, RO687148754 and RO687855854,55. Common characteristics of 
these ligands are that they carry three exit vectors at positions 3, 5 and 7 of the 
triazolopyrimidine core. While the position 3 residue is kept constant using a (2-
chlorophenyl)methyl moiety the other two positions are modified. Further structural diversity 
in the screening set was added by including a pyridine/pyrazine derived scaffold which carries 
generally 3 substituents in positions 2, 5 and 6 of the heteroaromatic core (RO684376656, 
RO6844112, RO5135445, RO6892033, RO703201957, FMP7234690, FMP7234691, 
FMP7234694, FMP7234698 and FMP7234699). For increasing the chance of engaging 
different signaling pathways, molecules with variations at all three exit vectors have been 
included. At position 2 the common denominator is a carboxylic acid amide group or as in case 
of pyridine RO6892033, a respective amide isoester. FMP7234690, FMP7234691, 
FMP7234694, FMP7234698 and FMP7234699 are decorated with different 
linker‑nitrobenzofurazan elements in position 2 which allows for investigating the influence of 
molecules with different sizes on signaling bias. To complete the structurally diverse set of 
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probes, a 2,4,5-trisubstituted pyridine derived class of novel CB2 ligands possessing a distinct 
and unique structure activity relationship as compared to the 2,5,6-trisubstituted 
pyridines/pyrazines was added (RO685000758, RO685345758 and RO692627459). The 
commonality of these ligands is a cyclopropyl ring in position 5 whereas the residues in 
positions 2 and 4 are different. RO6926274 carries on top a chlorine atom in position 6.  
In vitro pharmacology data 
Prior to studying their biased signaling fingerprint, the ligand test set has been subjected to in 
depth in vitro pharmacological profiling, including binding data, maximal ligand‑induced 
response (Emax) and half‑maximal response concentration (as pEC50) in cAMP production 
and β‑arrestin recruitment assays for both human CB1 and CB2 receptors (Table S2). These 
data were complemented by the respective mouse CB2 values in order to get an idea on 
potential species differences which are highly important for translating results from mouse in 
vivo pharmacology studies to humans. Most ligands have a very high affinity for the human 
CB2 receptor as assessed by competition binding studies using [3H]-CP55940 as a radioligand 
tracer. HU210 showed the highest affinity (hCB2 pKi = 9.78), closely followed by the 
structurally completely unrelated pyridine RO6853973 (hCB2 pKi = 9.45). The endogenous 
ligand anandamide exhibits the lowest affinity (hCB2 pKi = 6.91) for the human CB2 among 
the entire ligand set. Triazolopyrimdine RO6878558 is the second weakest human CB2 binder 
with a pKi of 6.94. Generally, pKi values for human and mouse CB2 are within the same range 
(Δ(pKi(hCB2) - pKi(mCB2)) = ± 0.5). A few ligands however show a significantly higher affinity 
for mouse than for human CB2 (cf. SR144528: pKi(hCB2) = 7.88 vs. pKi(mCB2) = 10.7; and 
RO6850007: pKi(hCB2) = 7.65 vs. pKi(mCB2) = 9.21). Interestingly, several CB2 binders with 
an opposite behavior are included in the compound set, having a higher affinity for human 
than for mouse CB2 receptor (cf. WIN55912-2: pKi(hCB2) = 8.57 vs. pKi(mCB2) = 7.28; and 
RO6844395: pKi(hCB2) = 7.67 vs. pKi(mCB2) = 6.87). With respect to the closely related 
human CB1, the library covers a broad range of affinities ranging from molecules with basically 
no interaction with human CB1 (cf. (S)‑AM1241, HU308 and RO7032019 with pKi(hCB1) 
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values < 5) to high affinity CB1 ligands such as THC (pKi(hCB1) = 8.48), HU210 (pKi(hCB1) 
= 9.55) and trisubstituted pyridine RO6853973 (pKi(hCB1) = 8.21). Some molecules show a 
preference for binding the human CB1 over the human CB2 receptor (cf. CP55940 10pKi(hCB2)-
pKi(hCB1) = 0.2). The endocannabinoid 2-AG is a balanced human CB1 and CB2 binder 
(10pKi(hCB2)-pKi(hCB1) = 1). However, the majority of tested ligands show a preference for human 
CB2. Highest CB2 binding selectivity is found for triazolopyrimidine RO6871487 (10pKi(hCB2)-
pKi(hCB1) = 436). Pyridine RO6843766 also exhibits a strong preference for human CB2 
(10pKi(hCB2)-pKi(hCB1) = 416), while HU308 is the most CB2 selective cannabinoid-derived ligand 
(10pKi(hCB2)-pKi(hCB1) = 278). The CB2 ligand library was furthermore profiled in cellular systems 
for functional read‑outs, such as modulation of cAMP levels in CB2‑overexpressing Chinese 
hamster ovary (CHO) cell lines. Several molecules from different chemotypes exhibited 
subnanomolar potencies on human CB2 (cf. HU210: cAMP pEC50(hCB2) = 9.45 and 
CP55940: cAMP pEC50(hCB2) = 10.33). The weakest tested ligand was again anandamide 
yielding a cAMP pEC50(hCB2) value of 5.93.  
Set of ligands with a range of activities 
To enhance the chance for getting a maximally diverse biased signaling fingerprint, the 
compound library was chosen in a way that it included agonists, partial agonists, as well as 
antagonists and inverse agonists (Table S2). For example, HU308 exhibits a cAMP 
Emax(hCB2) value of 98% and is therefore considered to be a full agonist on human CB2 
receptor (the effect of agonists is normalized to the effect of 10 μM CP55940 used as the 
reference full agonist). In addition, pyridine‑derived ligands were able to achieve full efficacy 
(cf. FMP7234691: cAMP Emax(hCB2) = 100%), as well as the endocannabinoids 2-AG and 
anandamide (cAMP Emax(hCB2) = 94% and 87%, respectively). In contrast, the efficacy of 
triazolopyrimidine RO6871487 reaches only 52% of the maximal effect and is therefore 
classified as partial agonist. Tetrasubstituted pyridine RO6926274 is an even weaker partial 
agonist, with a 38% maximal effect value. The strongest inverse agonism was found for 
AM630 (cAMP Emax(hCB2) = -152%) and SR144528 (cAMP Emax(hCB2) = -151%). Pyridine 
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RO7032019 was also classified as an inverse agonist (cAMP Emax(hCB2) = -92%). Potency 
for cAMP production by the human CB1 was low for many of the ligands (cf. JWH133: cAMP 
pEC50(hCB1) < 5; and RO6850007: cAMP pEC50(hCB1) < 5). In contrast, HU210, CP55940, 
and RO6853973 exhibit single digit nanomolar or even subnanomolar EC50 values (cAMP 
pEC50(hCB1) = 9.58, 9.73 and 8.12, respectively). All tested ligands behave either as full CB1 
agonists – with pyridines FMP7234691 and FMP7234690 showing even higher Emax values 
(cAMP Emax(hCB1) = 123% and 152%, respectively) than CP55940 at 10 μM – or partial 
agonists at the highest tested concentration of 10 μM. No antagonism nor inverse agonism for 
human CB1 was found.  
Receptor subtype variations of ligand activity 
With the exception of HU210 (10cAMP pEC50(hCB2) - cAMP pEC50(hCB1) = 1), all molecules show at least 
some functional selectivity when tested at the human CB1 and CB2 receptors. cAMP 
selectivity ratios, defined by 10cAMP pEC50(hCB2) - cAMP pEC50(hCB1), reached values up to > 3388 
(HU308). Functional selectivity was generally higher than binding selectivity (for exception cf. 
RO6843766: 10cAMP pEC50(hCB2) - cAMP pEC50(hCB1) = 168 vs. 10(pKi(hCB2)-pKi(hCB1) = 416). Most 
significant difference between cAMP and binding selectivity was observed for AM630 and 
WIN55912-2 (10cAMP pEC50(hCB2) - cAMP pEC50(hCB1) / 10pKi(hCB2)-pKi(hCB1) > 45 and 44, respectively). 
Potencies in the mouse cAMP assay range from highly active molecules (cf. CP55940: cAMP 
pEC50(mCB2) = 10.17; and RO6892033: cAMP pEC50(mCB2) = 8.39) to inactive ligands (cf. 
RO7032019: cAMP pEC50(mCB2) < 5). Generally, pEC50 data for human and mouse CB2 
receptors are within the same order of magnitude (pEC50(hCB2)-pEC50(mCB2) = 0 ± 1), 
especially when the molecules behave as strong partial or full agonists for the human receptor 
(cAMP Emax(hCB2) > 70%). Overall, efficacy for mouse CB2 tends to be lower than efficacy 
for human CB2. In particular, partial agonists for human CB2 are associated with lower 
potency for mouse CB2 (cf. RO6926274: cAMP pEC50(hCB2) = 8.15 vs. cAMP 
pEC50(mCB2) < 5). Such partial agonists for human CB2 tend to be weak partial agonists or 
neutral antagonists for mouse CB2 (cf. RO6853973: cAMP Emax(hCB2) = 45 vs. cAMP 
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Emax(mCB2) = 23; and RO6926274: cAMP Emax(hCB2) = 38 vs. cAMP Emax(mCB2) = 7). In 
several cases even a switch from agonism at human CB2 toward inverse agonism at mouse 
CB2 has been observed (cf. (R)-AM1241: cAMP Emax(hCB2) = 65 vs. cAMP Emax(mCB2) = -
22; and RO6850007: cAMP Emax(hCB2) = 63 vs. cAMP Emax(mCB2) = -48). Such changes can 
be of utmost importance when it comes to the interpretation of cAMP‑dependent efficacy 
mouse data in vivo. Interestingly, for the two enantiomers of AM1241, only (R)-AM1241 
showed a switch from agonism at human to inverse agonism at mouse CB2, while (S)-AM1241 
showed partial agonism at human and mouse CB2 (cAMP Emax(hCB2) = 78 vs. cAMP 
Emax(mCB2) = 35). Apart from cAMP read-outs, functional potency, efficacy and selectivity 
data in a β‑arrestin recruitment assay were generated for the library of ligands. β‑arrestin 
pEC50 values at human CB2 range from 8.39 (CP55940) to < 5 (cf. (rac)-AM1241). Potency 
for most molecules in hCB2 β‑arrestin recruitment assay is lower than in the hCB2 cAMP 
assay (cf. WIN55912-2: cAMP pEC50(hCB2) = 9.50 vs. β‑arrestin pEC50(hCB2) = 7.93). With 
regard to efficacy, once again the whole spectrum ranging from inverse agonism (cf. AM630: 
β‑arrestin Emax(hCB2) = -124%), passing by partial agonism (cf. (R)-AM1241: β‑arrestin 
Emax(hCB2) = 29%), toward full agonism (cf. CP55940: β‑arrestin Emax(hCB2) = 80%) is 
covered by the ligand set. Between the two endocannabinoids, 2-AG behaves as a stronger 
partial agonist than anandamide (cf. 2-AG: β‑arrestin Emax(hCB2) = 38%; 2-AG: β‑arrestin 
Emax(hCB2) = 80%). Based on the available data, inverse agonism in the human CB2 cAMP 
assay translates into inverse agonism in the human CB2 β‑arrestin recruitment assay. A 
similar trend was observed for agonism. However, full agonists in the human CB2 cAMP assay 
possess, in most cases, a lower Emax value in the human CB2 β‑arrestin recruitment assay (cf. 
(S)-AM1241: cAMP Emax(hCB2) = 78% vs. β‑arrestin Emax(hCB2) = 29%). In the human CB1 
β‑arrestin recruitment assay, CP55940 was the most potent (β‑arrestin pEC50(hCB1) = 7.96), 
while several ligands possess pEC50 values below 5 (cf. (S)-AM1241 and HU308). CP55940 
represented the most efficacious agonist (β‑arrestin Emax(hCB1) = 94%) of the test set, and 
JWH133 was a partial agonist (β‑arrestin Emax(hCB1) = 40%). Although SR144528 and AM630 
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did not have an effect on CB1-mediated cAMP signaling, they showed inverse agonism in 
β‑arrestin recruitment assay (SR144528 β‑arrestin Emax(hCB1) = -82%; AM630: β‑arrestin 
Emax(hCB1) = -120%) The selectivity of CB2 vs. CB1 β‑arrestin recruitment ranges from poorly 
selective CP55940 (10β‑arrestin pEC50(hCB2) - β‑arrestin pEC50(hCB1) = 3), to highly selective SR144528 
(10β‑arrestin pEC50(hCB2) - β‑arrestin pEC50(hCB1) = 316). Representative mouse CB2 β‑arrestin recruitment 
data range from molecules with pEC50 values of 8.02 (CP55940) to values below 4.5 (cf. 
SR144528). For all tested molecules, potency at the mouse CB2 β‑arrestin recruitment assay 
was lower than at the human CB2, as well as at mouse CB2 cAMP assay. Most efficacious 
agonist was CP55940 (β‑arrestin Emax(mCB2) = 96). In summary, the ligand test set provides 
maximal diversity, not only with regard to the chemical structure of the molecules, but also to 
its in vitro pharmacology profile. Ligands with subnanomolar affinities for both human and 
mouse CB2 receptors are included, as well as molecules with weaker affinity. Binders with a 
slight preference for CB1, and highly selective CB2 ligands are part of the library. Regarding 
functional potency, a broad range of pEC50 values, both for cAMP and β‑arrestin recruitment, 
is covered. Importantly, the complete efficacy space, ranging from inverse agonism to full 
agonism, was displayed for both read‑outs. Therefore, the ligand test set is ideally suited for 
identifying different biases in signaling fingerprints. 
Early absorption, distribution, metabolism and excretion (ADME) profile 
To assess the diversity of the ligand test set with regard to its physicochemical properties and 
as a preparation for potential in vivo follow‑up studies for exploring whether differences in 
biased signaling result in different pharmacodynamic effects, early adsorption, distribution, 
metabolism and excretion (ADME) data were generated (Table S3). Exposing CB2 in the 
respective target tissue after systemic routes of administration is a pre‑requisite for carrying 
out such in vivo studies. To achieve high exposures, especially favourable lipophilicity, 
membrane permeation and microsomal stability values are of high relevance and were, 
therefore, key elements of this assessment. The ligands are highly diverse in their molecular 
weight (MW), covering a range from 310.4 (cf. cannabinol) to 841.0 g/mol for the CB2 ligand 
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FMP7234698 which, besides a CB2 recognition element, also contains a spacer and a 
fluorescent nitrobenzofurazan moiety, while optimal MW for achieving high bioavailabilities is 
below 500 g/mol. In addition, the ligand set is extremely diverse in their polar surface area 
(PSA). The almost pure hydrocarbon molecule JWH133 exhibits the lowest PSA value of 
7.9 Å2, while polyethylenglycol-derived FMP7234698 possesses a very high PSA of 176.9 Å2. 
The maximum number of hydrogen bond donors (HBDs) within the library is two (cf. 
anandamide and RO6853457). Several of the selected molecules do not contain a hydrogen 
bond donating element at all (cf. AM630 and RO6435559). In case where barriers, such as 
the blood brain barrier or the blood retina barrier, need to be crossed, molecules with a PSA 
< 75 Å2 and a low number of HBDs will be preferred60,61. 
Since the endogenous cannabinoid receptor ligands, 2-AG and anandamide, are fatty acid 
derivatives, their lipophilicity is high. This is reflected by their calculated octanol/water partition 
coefficients (Kow clogP) of 6.7 and 6.3, respectively. The corresponding values of the synthetic 
ligands SR144528 (9.2), HU308 (9.0) and especially pyridine FMP7234699 (11.3), which 
contains a hydrocarbon spacer between nitrobenzofurazan dye and CB2 recognition element, 
are higher. Interestingly, CB2 tolerates a tremendous range of polarities, since the highly polar 
pyridine bis-amide RO7032019 (Kow clogP = 1.5) is, like FMP7234699, a tight binder. 
Experimentally generated octanol/water distribution coefficients (logD) are often lower than its 
corresponding calculated Kow clogP values, ranging from 2.5 (RO7032019) to 4.29 (HU308). 
Because charges affect measured logD values, but are not reflected in predicted Kow clogP 
numbers, differences between logD and Kow clogP values are generally higher for molecules 
that are charged under physiological conditions (pH 7.4) e.g. as found for (S)‑AM1241 (logD 
= 3.64 vs. Kow clogP = 5.7) carrying a basic piperidine moiety (pKa = 7.8). Most of the molecules 
in our ligand set are either uncharged or carry a basic center, whereas only cannabinol, 
CP55940 and pyridine RO6850007 contain weakly acidic phenol or amide moieties. 
Compound solubility was assessed using lyophilisation solubility assay (LYSA)62. Kinetic 
solubility in aqueous buffer is the highest for pyridine derived bis-amide RO6853457 (LYSA = 
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92 μg/mL). For the endocannabinoids and the cannabinoid‑derived ligands LYSA values are 
generally poor (cf. 2-AG: LYSA = < 0.5 μg/mL; or JWH133: LYSA = < 0.4 μg/mL). The 
molecules’ potential for passive membrane permeation was investigated using the parallel 
artificial membrane permeability assay (PAMPA) model63. Highest permeation coefficients Peff 
were found for the two highly drug-like pyridines RO7032019 (Peff = 6.4 x 10-6 cm/s) and 
RO6853457 (Peff = 3.9 x 10-6 cm/s), with their efficient passive permeation also reflected by a 
high propensity for permeating to the acceptor compartment (%Acc.) value of 12% for both 
molecules. Anandamide was also able to passively permeate membranes (Peff = 0.26 x 10-6 
cm/s). In contrast, molecules with higher Kow clogP, such as SR144528 and CP55940, had a 
high propensity for sticking to the membrane (%Mem. = 54% and 47%, respectively) rather 
than permeating to the acceptor compartment (%Acc. = 0% for both molecules), leading to a 
permeation coefficient value of zero for both molecules.  
Clearance rates of the CB2 ligands were determined in co‑incubation experiments with liver 
microsomes, providing first predictions of doses needed for reaching sufficient target tissue 
exposure for future in vivo follow‑up studies (low to medium clearances (CL) translate into low 
doses). In general, clearance values in human are lower than in rodent liver microsomes. 
Highest human microsomal CL was obtained for (R)-AM1241 (304 μL/min/kg). In mouse 
microsomes WIN55912-2 and CP55940 were least stable (CL = 745 μL/min/kg for both 
molecules). The most stable molecule in human, as well as in mouse microsomes, is pyridine 
RO7032019, which originates from a drug‑discovery program (CL = 10 μL/min/kg in both 
species). CB2 inverse agonist AM630 and agonists HU308 and JWH133 have been exploited 
in various mouse disease models. While mouse hepatocyte CL values are high for AM630 
(101 μL/min/million cells), low clearances were determined for HU308 (5 μL/min/million cells) 
and JWH133 (8 μL/min/million cells). In human hepatocytes all three molecules exhibit low to 
medium clearances. In case of AM630 and JWH133, clearance in hepatocytes is lower than 
in microsomes (AM630: hum. mic. CL = 82 μL/min/kg vs. hum. hep. CL = 18 μL/min/million 
cells; and JWH133: mouse mic. CL = 63 μL/min/kg vs. hum. hep. CL = 10 μL/min/million cells). 
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This observation can likely be attributed to the tight protein binding being reflected by the low 
free fractions found in both the human and the mouse plasma protein binding assays (AM630: 
free fraction (%) human/mouse = <0.1/0.4; and JWH133: free fraction (%) human/mouse = 
<0.1/<0.1). Free fraction usually increases with higher molecule polarity, and this trend can be 
observed in the cannabinoid receptor ligand test set, where for more polar (S)-AM1241 (Kow 
clogP = 5.7, logD = 3.64) a free fraction of 0.5% in human and of 1.2% in mouse plasma 
protein binding assay was determined, whereas less polar JWH133 (Kow clogP = 8.5, logD > 
3) exhibits free fractions below 0.1% in both species. Neither (S)‑AM1241 nor JWH133 are 
substrates for the mouse P-glycoprotein (P‑gp) transporter ((S)-AM1241: (P-gp) mediated 
efflux ratio mouse = 1.4; JWH133: (P‑gp) mediated efflux ratio mouse = 1.7), making them 
capable for crossing biological barriers such as the blood brain barrier, something that might 
become important when signaling bias is investigated in mouse models of neuroinflammatory 
diseases. In contrary, SR144528 and HU308 are interacting with the P‑gp transporter 
(SR144528: (P‑gp) mediated efflux ratio mouse = 5.6; HU308: (P‑gp) mediated efflux ratio 
mouse = 7.3) and are, therefore, less suitable for being applied in brain disease models as 
they would require higher doses to compensate for the efflux. Overall, the biased signaling 
fingerprint ligand test set covers an extremely broad range of physicochemical, as well as 
early ADME properties. 
Signaling fingerprint of CB1 and CB2 
Using a BRET-based signaling platform64–66, we assessed the signaling repertoire of both CB1 
and CB2 toward 13 G protein and the 2 β‑arrestin subtypes in response to the agonists 
CP55940 for CB1 and JWH133 for CB2. Gs protein activation was assessed by monitoring 
decrease of BRET signal upon dissociation of Gαs and Gβ1γ2 subunits64,67, while activation of 
other G protein subtypes was measured as an increase in BRET signal upon recruitment of a 
subtype-specific signaling effector to the plasma membrane66. Similarly, recruitment of 
β‑arrestins to the receptors was monitored as β‑arrestin translocation from cytosol to the 
plasma membrane65. Both cannabinoid receptors couple primarily to the Gi/o family of G 
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proteins and recruit β‑arrestin2 more strongly than β‑arrestin1 upon activation (Figure 1; Table 
S7). In addition, CB1 activates the atypical Gi/o family member Gz and well as G12/13 and G15. 
No activation of the Gs or any members of Gq family apart from G15 was observed. Both CB1 
and CB2 only negligibly promote β‑arrestin trafficking to endosomes upon receptor 
internalization as assessed by enhanced bystander BRET65, in contrast with the strong 
translocation promoted by the vasopressin V2 receptor (Figure 2).  
For each of the pathways activated by cannabinoid receptors, a concentration‑dependent 
response was measured for a selection of ligands. While 35 ligands were tested for 
CB2‑mediated signaling, only eight ligands, which were not CB2 selective, were tested for 
CB1‑mediated signaling. Maximal ligand‑induced response (Emax) and half‑maximal response 
concentration (as pEC50) were obtained for each ligand (Table S8 and S9). In order to allow 
comparison of each ligands’ effect on different signaling pathways, the Emax value for each 
ligand was normalized to the value of the reference ligand WIN55212‑2. The same reference 
ligand was used to calculate bias factors using the operational model of bias agonism68 (Table 
S15 and S17).  
CB1 signaling 
When considering the maximal ligand-promoted β‑arrestin recruitment (Emax), all compounds 
were more efficacious for β‑arrestin2 than β‑arrestin1, except for 2‑AG where β‑arrestin1 
response is about 40% higher than that of β‑arrestin2 (Figure 3). Interestingly, 2-AG is also 
the only compound that generated a larger response for the two β‑arrestins than for the G 
proteins, indicating a clear preference for β‑arrestin signaling. Regarding G protein activation, 
most compounds had similar relative efficacies (Emax) toward the different subtypes (Figure 3, 
left). Notable exceptions includes cannabinol, which, in contrast to all other compounds, acts 
as an inverse agonist on G15 response. Other differences include the Gi1 response to THC and 
cannabinol, which was generally low for the other compounds, but is among the most 
efficacious compared to the other G protein subtypes for these two ligands. Response of G15 
and G12 was also generally lower, except for 2‑AG and CP55940. When looking at potencies 
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(pEC50 values, Figure 3, right), a general trend of higher pEC50 for the Gi/o family of G proteins 
is observed across the tested ligands, with a clear separation across 3 logarithmic units visible 
for 2‑AG: Gi/o < G12/13 = G15 < β‑arrestins. A wide range of potencies is also observed for 
cannabinol‑induced signaling via CB1, although without clear separation between potencies 
for activation of distinct G protein subtypes (Figure 3, right).  
Based on efficacy only, 2‑AG showed slight preference towards recruitment of β‑arrestins than 
activation of G proteins, clearly visible from the obtained concentration‑response curves 
(Figure 4). Thus, even when a maximal activation of G proteins is reached (1-10 µM), further 
increase in 2‑AG concentration can lead to a change in signaling output due to more 
efficacious β‑arrestin activation. In contrast, another endocannabinoid anandamide showed 
higher efficacy for activation of Gi2, GoB and G13 than other tested pathways (Figure 4).  
Based on bias factors calculated using WIN55212-2 as a reference, all the tested ligands are 
generally balanced (Table S15). CP55940, nabilone, and anandamide are slightly biased 
towards Gi2 than Gi1, and cannabinol preferentially activates β‑arrestin1: β‑arrestin1 > G12 > 
Gi3 = Gi1 = G13 = Gi2 = GoA = GoB > β‑arrestin2 > Gz.  Although modest differences in relative 
efficacies toward different G proteins were observed among the compounds, calculated bias 
factors vs. WIN55212-2 did not reach statistical significance (Table S15). 
CB2 signaling 
In contrast to CB1 receptor signaling, larger differences across the signaling repertoire of the 
CB2 were observed for the ligands tested (Figure 5).  
Focusing on efficacies and potencies of compounds (Figure 5), most ligands activating all 
tested pathways. However, several ligands activated only G proteins, without detectable 
β‑arrestin recruitment: RO6883666, RO6853973 and RO6926274. Regarding G protein 
activation, Gi1 is sometimes recruited with lower efficacy than other G proteins (Figure 5). 
2‑AG, anandamide, RO6892033 and to a lower extent CP55940, HU210 and JWH133 evoke 
stronger response at β‑arrestin than G proteins. While pyridine-derived RO6892033 does not 
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recruit β‑arrestin2, β‑arrestin1 might be slightly preferred over G proteins (pEC50 similar, but 
more efficacious). In addition, RO6869094 showed preference towards β‑arrestin1 than any 
other pathway, based on both Emax and pEC50.  
When considering the maximal ligand‑induced CB2‑mediated β‑arrestin1 and β‑arrestin2 
response (Figure 5), 2‑AG produces similar Emax values for β‑arrestin1 and β‑arrestin2, 
whereas anandamide evokes a robust β‑arrestin1, but only a minor β‑arrestin2 response. 
Furthermore, endocannabinoid anandamide is less potent for β‑arrestin1 than G proteins and 
especially β‑arrestin2 (Figure 5, Table S9). The signaling preference of endocannabinoids 2-
AG and anandamide is well illustrated in the concentration‑response curves presented in 
Figure 6. Whereas 2‑AG clearly showed preferences towards both β‑arrestins vs. G proteins, 
anandamide showed preference only towards β‑arrestin1 in comparison with other tested 
pathways (Figure 6).  
Interesting signaling profiles were observed for distinct enantiomers and racemic AM1241. 
While (R)‑AM1241 recruits only β‑arrestin2 (Emax = 29%), (S)‑AM1241 recruits both β‑arrestins 
with a minor preference towards β‑arrestin2 (β‑arrestin1 Emax = 58%, β‑arrestin2 Emax = 79%). 
However, racemic AM1241 activates β‑arrestin1 stronger than β‑arrestin2 (β‑arrestin1 Emax = 
39%, β‑arrestin2 Emax = 20%), with β‑arrestin2 response being lower than for either of the 
enantiomers. This observation is in accordance with the findings of Soethoudt et al.38 
As for CB1, relative effectivenesses (Table S16) and bias factors using WIN55212‑2 as a 
reference (Table S17) were calculated for CB2. Three groups of ligands could be identified by 
hierarchical clustering of the calculated bias factors of the ligands (Figure S1). The first group 
have similar signaling properties as the reference ligand WIN55212‑2, including HU210 and 
nabilone. The second group included ligands with signaling reduced more or less uniform 
across the observed signaling pathways (Gi1-3, GoA, GoB, β‑arrestin1 and β‑arrestin2). This 
group included HU308 and JWH133, among other ligands. The third group that included THC, 
cannabinol, 2-AG and anandamide among others had a more pronounced biased signaling 
profile. All of these ligands had β‑arrestin signaling affected more strongly compared to G 
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protein signaling, effectively making them G protein biased. In this group, compounds 
RO6843766, RO6926274 and RO6853973 did not recruit arrestin, while RO7234687 was 
active only towards Go family.   
Several of the tested ligands show a bias towards β‑arrestin1 over β‑arrestin2 when compared 
to the reference ligand WIN55212‑2: RO6871487 > RO6869094 ≈ RO6892033 > cannabinol 
≈ RO6878558 ≈ FMP7234698 ≈ (R)‑AM1241 ≈ RO6435559. While cannabinol, anandamide, 
RO6892033 and 2‑AG are slightly biased towards GoB over β‑arrestin2, RO6883666 and 
cannabinol are biased towards GoB over GoA. JWH133 is slightly biased towards Gi1 vs. Gi2 and 
towards GoB vs. Gi2, RO6883666 and cannabinol are biased towards GoA over Gi2, while none 
of the ligands show any bias between Gi2 and Gi3. RO6853457, cannabinol and RO6892033 
are slightly biased towards Gi2 over β‑arrestin2, cannabinol and anandamide towards Gi2 over 
β‑arrestin1. A few ligands are biased towards β‑arrestin1 vs. Gi2: RO6871487 ≈ RO6853973 
> RO6869094 ≈ FMP7234698 ≈ (R)‑AM1241 ≈ RO6843766 ≈ JWH133. 
CB2 signaling can be biased by mutations in the ligand binding site 
In addition to using structurally different ligands to induce biased signaling response upon 
activation of CB2, we tested the hypothesis that mutations within the ligand binding pocket 
can influence the receptor signaling. Using Arpeggio web server for calculating interatomic 
interactions in protein structures69, we detected and visualized interactions between CB2 
model and a potent agonist HU210, identifying bulky and hydrophobic residues making the 
most extensive contacts with the receptor ligand binding pocket (F87, F94, F183, W194, F281; 
Figure S2). Those residues were mutated into alanine, and the effect of mutations on the 
receptor signaling profile upon activation with HU210 was monitored using the BRET 
biosensors (Figure 7). Mutations had dramatic and distinct effects on the signaling profile of 
CB2 suggesting a role for some of these residues in directing functional selectivity. Mutation 
W194A completely abolished receptor signaling via Gi2 and β‑arrestin2. F87A lowered the 
receptor’s affinity for G protein activation more than for β‑arrestin recruitment, making the 
receptor preferentially signal via β‑arrestin. Two mutations, F183A and F281A, affected only 
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β‑arrestin2 and not β‑arrestin1, either via reduced maximal ligand-induced response (F281A) 
or reduced ligand potency (F183A) (Figure 7). F94A did not alter CB2 signaling. 
 
Discussion  
The set of 35 ligands we used contains representatives from 9 different chemotypes which 
are very diverse not only with regard to their chemical structure, but also with regard to their 
in vitro pharmacology profile and physicochemical properties.  
We confirmed that both cannabinoid receptors activate the Gi/o family of G proteins. In addition, 
CB1 also activated Gz, G12/13, and G15 although we did not observe activation of other members 
of the Gq family (Gq, G11, G14) upon stimulation by CP55940. We also have not observed 
activation of the Gs reported previously28. As Gs signaling was only observed at a very high 
receptor density in the previous study, the most likely explanation for this difference is that Gs 
coupling is weak and could not be observed at receptor expression levels used in our study. 
Both receptors preferentially recruit β‑arrestin2 over β‑arrestin1, and β‑arrestins only weakly 
traffic to the endosomes with the receptors upon internalization. This is consistent with both 
CB1 and CB2 classified as class A (in arrestin-recruitment) GPCRs interacting transiently with 
β‑arrestins when compared to V2R, which is a class B GPCR interacting stably with 
β‑arrestins70. A highly discussed question regards β‑arrestin recruitment by classical 
cannabinoids containing dibenzopyran ring, which are either phytocannabinoids or their 
synthetic analogues. While Dhopeshwarkar and Mackie32 observed CB2‑mediated β‑arrestin 
recruitment only by nonclassical cannabinoids, Soethoudt et al.38 claiming that both classical 
and nonclassical cannabinoids recruit β‑arrestins to a certain extent, although both studies 
used PathHunter® β-arrestin assay in CHO cells (DiscoverX). Our data confirm that both 
classical and nonclassical cannabinoids are capable of recruiting β‑arrestins, where an 
extensively used classical phytocannabinoid-derived ligand, JWH133, showed significant 
β‑arrestin recruitment via CB2, which is comparable to that of non‑classical CP55940. 
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Compared to THC, JWH133 is lacking a hydroxyl group at position 1 of dibenzopyran ring and 
has a branched and by one CH2 moiety shorter aliphatic tail at position 3 (Table S1). However, 
in our study phytocannabinoids THC and cannabinol only weakly recruited β‑arrestin2, without 
measurable β‑arrestin1 recruitment. HU210 is structurally very similar to JWH133 in having 
the same branched aliphatic tail at position 3, but has the aliphatic tail two carbons longer than 
the THC (Table S12). The branched aliphatic groups interact with the residues 87, 183 and 
281 that are important for arrestin vs. G protein signaling, and also makes strong interaction 
with the W194 at the tip of the aliphatic chain – perhaps explain the dramatic difference in 
activity between THC and HU210. This suggests that small variations in the ligand structure 
can have a significant impact on the ability of CB receptors to recruit arrestin, reflecting the 
observed weaker arrestin recruitment by CB receptors compared to the “strong” recruiters, 
such as V2R.  
Most ligands were more potent in activation of Gi/o proteins than recruitment of β‑arrestins. 
Although THC weakly recruited β‑arrestins, it was one of the strongest Gi1 activators via CB1. 
In case of CB1, which also activates other G protein subtypes, ligands were generally less 
potent in activating those (eg. G12 and G15) than Gi/o protein members, but more potent than 
in β‑arrestin recruitment. In case of CB2, synthetic cannabinoids HU210, HU308, 
WIN55212‑2, JWH133 and CP55940, as well as the endocannabinoid 2‑AG were among the 
highest‑efficacy ligands. Only weak recruitment of β‑arrestins was detected by cannabinol, 
reflecting its structural similarity to THC. Interestingly, phytocannabinoid-derived cannabinol 
acted as an inverse agonist on CB1‑mediated G15 activation, while being an agonist for other 
pathways.  
Furthermore, we found the signaling of the endogenous ligand 2‑AG to prefer β‑arrestin 
recruitment over G protein activation at both cannabinoid receptors, as judged by the 
amplitude of the response (efficacy). Although bias factors based on the operational model 
indicate weakened signaling due to lower potency at signaling via β‑arrestins compared to G 
proteins, efficacy at higher 2‑AG concentrations drove the signaling towards β‑arrestin. It is 
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important to note that operational model does prioritize potency shifts over efficacy, and 
therefore may not accurately reflect activity of the weak affinity ligands such as 
endocannabinoids. Similar behavior occurring only at CB2‑mediated β‑arrestin1 recruitment 
was also observed with another endogenous ligand, anandamide. Reported 2‑AG and 
anandamide concentrations in human blood are in the nanomolar range71, with possibly higher 
local concentrations around the transmembrane receptors due to their high lipophilicity. 
Therefore, the range of ligand concentrations used within our study corresponds to the 
physiological endocannabinoid concentrations. Given the importance of GPCR 
desensitization via arrestin‑dependent internalization, as well as the arrestin-mediated 
signaling, the observation of endocannabinoids preferentially activating β‑arrestins over G 
proteins at higher ligand concentrations as judged by higher amplitudes of the responses could 
hold answers to physiological regulation of endocannabinoid system signaling. 
The two tested CB2 inverse agonists, AM630 and SR144528, evoked stronger inhibition on 
signaling via Gi proteins than Go proteins and β‑arrestins, suggesting that CB2 constitutive 
activity is composed mostly of Gi protein signaling, or that those inverse agonists are less able 
to inhibit signaling via other G proteins. Although the inverse agonists mainly inhibited Gi 
signaling, constitutive activity of CB2 via β‑arrestin pathway was also suppressed, indicating 
receptor’s constant desensitization and/or constant β‑arrestin mediated signaling.  
Relative effectiveness and bias factors were calculated for all the tested ligands and pathways 
using the operational model of biased agonism (Tables S14–S17). Although this method has 
an advantage of comparing ligand bias independently of the biological system used to asses 
signaling72, one needs to be mindful when interpreting the results due to the large error 
propagation of the calculated bias factors (Table S15 and Table S17). We have observed 
classification of ligands into three broad classes of full agonists, agonists with reduced activity 
across board (eg. partial agonists) and agonists with “unbalanced” activity changes, eg. biased 
agonists (Figure S1). While strong correlation was observed among Gi family members, 
somewhat reduced correlation was observed between Gi vs. Go, Gi vs. -arrestin and among 
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Go family responses (Figure S3). The weakest correlation was observed between the two -
arrestin responses (Figure S3). This suggests that, while it is nearly impossible to evoke a 
bias between Gi1 and Gi2, for example, it is possible to develop a Gi vs. arrestin or even Gi vs. 
Go biased ligands.    
Conclusion 
Our detailed analysis of G protein activation and β‑arrestin recruitment by CB1 and CB2 
receptors showed an unexpected pleiotropy of signaling preferences by different ligands. This 
observation is consistent with the results of Wouters et al.39, who demonstrated that CB1 
readily recruits arrestin with a set of 21 synthetic CB1 ligands, and that its signaling can be 
biased depending on the structure of the ligand used. For example, we show that the alkyl 
groups that are specific to HU210 relative to THC interact with the residues involved in biased 
signaling. Importantly, we showed that the endocannabinoids show significant preference 
towards arrestin recruitment, relative to the available synthetic cannabinoids and 
phytocannabinoids. Our data also imply that it is possible to derive artificial ligands with 
specific biased signaling properties both useful for the understanding of the biology of 
endocannabinoid system, as well as for therapeutic use. In addition, by introducing mutations 
within the ligand binding pocket, we showed that disturbing receptor-ligand interactions can 
result in altered signaling profile and receptors biased towards G protein or β‑arrestin 
signaling. Taken together, our data suggests that CB2 signaling can be readily influenced by 
the respective interacting ligands of diverse structures, providing a possible explanation for 
the complex physiological effects described for CB2 activation. It further confirms the 
importance of ligand structure and the interactions they form with the receptor in signaling, 
making it possible to design ligands with desired signaling outcome.    
More research is needed to understand which signaling pathways downstream of cannabinoid 
receptors are pathologically important, and which could be pharmacologically exploited. At the 
same time, more structural data are needed to link the ligand binding pose and the interactions 
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it makes to the receptor to its signaling properties – but this link definitely exists.  Novel artificial 
ligands reported here can be used as powerful tools to study the effects of biased signaling in 
inflammatory cell or animal models, due to their favourable physicochemical properties and 
metabolic stability. Eventually, the data collected in this study can be utilized to design 
therapeutics that boost signaling only via the required pathway, leading to health improvement 
with less side effects.  
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Figure 1. G protein activation and β‑arrestin recruitment by CB1 and CB2: maximal 
ligand‑induced response (Emax) in ΔBRET signal upon receptor stimulation with agonist 
(0.5 µM CP55940 for CB1, 0.34 µM JWH133 for CB2). Positive ΔBRET indicates activation of 
a specific pathway. For G protein activation and β‑arrestin recruitment, relocation of signaling 
effector to the plasma membrane was monitored. For activation of Gs protein, dissociation of 
Gα subunit from Gβγ was monitored. Mean and standard error of mean are shown, data from 
Table S7. CB1 couples to Gi/o family, Gz, G15 and G12/13. CB2 couples to Gi/o family of G 
proteins. Both receptors recruit β‑arrestin2 more strongly than β‑arrestin1.  
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Figure 2. β‑arrestin trafficking to the endosomes upon receptor internalization, monitored as 
relocation of β‑arrestin to the endosomal membrane. Both cannabinoid receptors show 
negligible β‑arrestin recruitment in endosomes when compared to vasopressin V2 receptor 
(V2R), a strong β‑arrestin recruiter.  
 
Figure 3. Characterization of ligand-induced CB1 signaling: dot-charts showing maximal 
relative ligand-induced response values (Emax) normalized to WIN55212‑2 (left) and negative 
logarithm of half‑maximal response concentration (pEC50) for all the tested pathways. Only 
mean values of three independent experiments are shown, data from Table S8. 
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Figure 4. Concentration-dependent CB1-mediated activation of G proteins and β‑arrestins by 
endocannabinoids anandamide (left) and 2-AG (right). Signal response is normalized to 
reference ligand WIN55,212‑2. Mean and standard error of mean are shown, data from Table 
S10 and Table S11. 
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Figure 5. Characterization of ligand‑induced CB2 signaling: dot‑charts showing maximal 
relative ligand‑induced response values (Emax) normalized to WIN55212‐2 (top) and negative 
logarithm of half‑maximal response concentration (pEC50, bottom) for all the tested pathways. 
Mean values of three independent experiments are shown, data from Table S9. 
 
Figure 6. Concentration‑dependent CB2‑mediated activation of G proteins and β‑arrestins by 
endocannabinoids anandamide (left) and 2‑AG (right). Signal response is normalized to 
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reference ligand WIN55,212‑2. Mean and standard error of mean are shown, data from Table 
S12 and Table S13. 
 
Figure 7. Agonist‑induced signaling of CB2 mutants: dot‑charts showing maximal relative 
HU210‑induced response values (Emax) normalized to the wild-type receptor (left) and negative 
logarithm of half‑maximal response concentration (pEC50) subtracted from wild-type CB2 
value for each pathway (right). Mean values of three independent experiments are shown. 
Concentration-dependent signaling shown in Figure S4.  
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Materials and Methods: 
Ligands. 2‑AG, anandamide, Δ9‑THC, nabilone and HU210 were purchased from Toronto 
Research Chemicals, Canada. Cannabinol, (+)‑WIN55,212‑2 (mesylate), (‑)‑CP55,940, 
(R)‑AM1241, (S)‑AM1241 and (rac)‑AM1241 were purchased from Cayman Chemical, USA. 
JWH133, HU308, AM630, SR144508 were purchased from Cedarlane‑Tocris, Canada. 
Structures, IUPAC names and CAS numbers of the screened compounds are given in Table 
S1.  
General procedure. All reactions were performed using oven or flame‑dried glassware and 
dry solvents. Reagents were purchased from Sigma Aldrich, Acros, Alfa Aesar, Apollo 
Scientific, TCI, or Merck, and used without further purification unless noted otherwise. All 
moisture‑sensitive reactions were performed under a nitrogen atmosphere. 1H-NMR and 13C-
NMR spectra were recorded either on AV 300 MHz, on AV 600 MHz or on AV 750 (for 
cryoprobes) from Bruker. Chemical shifts are recorded in parts per million (ppm). Spin 
multiplicities are described as s (singlet), d (dublet), t (triplet), q (quartet), dq (doublet of 
quartets) and m (multiplet). Coupling constant (J) are recorded in Hz. NMR data were analyzed 
with MestReNova software. All 13C-NMR-spectra were recorded with 1H‑broad‑band 
decoupling. All chemical shifts are reported in ppm relative to tetramethylsilane (δ = 0.00 ppm) 
and were calibrated with respect to their respective deuterated solvents. High‑resolution mass 
spectra (HRMS) were recorded on an Agilent Technologies 6220 Accurate Mass TOF LC-MS 
apparatus linked to Agilent Technologies HPLC 1200 Series, using Thermo Accuore RP-MS 
column. Liquid chromatography–mass spectrometry (LC-MS) analysis were performed on an 
Agilent Technologies 6120 Quadrupole LC-MS apparatus linked to Agilent Technologies 
HPLC 1290 Infinity, using Thermo Accuore RP-MS column. Flash chromatography was 
performed using SiliCycle silica gel type SiliaFlash P60 (230 – 400 mesh). TLC analysis was 
performed on Merck silica gel 60/Kieselguhr F254, 0.25 mm. 
Synthesis of RO6844112, methyl N-{6-[(4-fluorophenyl)methyl]pyridine-2-carbonyl}-L-
leucinate. 
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A mixture of 6-(4-fluorobenzyl)picolinic acid (CAS number 1415899-72-7; 20 mg, 86.5 µmol), 
(S)-methyl 2-amino-4-methylpentanoate hydrochloride (CAS number 7517-19-3; 18.9 mg, 104 
µmol), 1-hydroxybenzotriazoloe hydrate (26.5 mg, 173 µmol) and N-ethyl-N-isopropylpropan-
2-amine (44.7 mg, 60.4 µL, 346 µmol) in N,N-dimethyl formamide (400 µL) was stirred at 
ambient temperature for 16 h. The reaction mixture was poured onto 1 M HCl / ice water 1:1 
(1 x 20 mL) and extracted with ethyl acetate (2 x 25 mL). The combined extracts were washed 
with ice water (2 x 25 mL), dried over Na2SO4 and filtered off. The solvent was removed under 
reduced pressure to give the crude which was purified by preparative thin layer 
chromatography (silica gel, 2.0 mm, heptane / ethyl acetate 2:1, elution with ethyl acetate) to 
give the title compound (23 mg, 74%) as colorless liquid. 1H NMR (500 MHz, DMSO-d6) δ 
8.71 (br d, J=8.2 Hz, 1H), 7.89 - 7.95 (m, 1H), 7.82 - 7.87 (m, 1H), 7.48 (dd, J=7.6, 0.8 Hz, 
1H), 7.37 - 7.43 (m, 2H), 7.08 - 7.17 (m, 2H), 4.56 (ddd, J=10.0, 8.3, 4.6 Hz, 1H), 4.20 (s, 2 
H), 3.66 (s, 3H), 1.83 (ddd, J=13.4, 10.0, 4.9 Hz, 1H), 1.62 - 1.70 (m, 1H), 1.55 - 1.63 (m, 1H), 
0.90 (dd, J=17.5, 6.4 Hz, 6H). 13C NMR (500 MHz, DMSO-d6) δ 172.8, 164.0, 161.2, 160.0, 
148.9, 138.9, 135.7, 131.3, 126.4, 120.0, 115.5, 52.4, 50.7, 42.6, 40.1, 24.8, 23.1, 21.7. HRMS 
(pos. ESI): m/z calculated for C20H23FN2O3 [M+H]+ 359.1771, found 359.1771. 
Synthesis of RO5135445, methyl N-[6-(cyclobutylmethoxy)-5-(pyrrolidin-1-yl)pyrazine-
2-carbonyl]-L-valinate.  
  
A solution of bromo-tris-pyrrolidino phosphoniumhexafluorophosphate (PyBOP) (156 mg, 0.3 
mmol) in N,N-dimethylformamide (0.5 mL) was added to a solution of 6-cyclobutylmethoxy-5-
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pyrrolidin-1-yl-pyrazine-2-carboxylic acid (CAS number 1017603-71-2; 62 mg, 0.2 mmol) in 
N,N-dimethylformamide (1 mL). The mixture was shaken for 20 minutes. L-Valine methyl ester 
(CAS number 4070-48-8; 52 mg, 0.4 mmol) and N-ethyldiisopropylamine (DIPEA, 103 mg, 0.8 
mmol) were added portion-wise and the reaction mixture was shaken for 16 hours. The solvent 
was removed in vacuo and the crude product was purified by preparative HPLC to afford 
methyl N-[6-(cyclobutylmethoxy)-5-(pyrrolidin-1-yl)pyrazine-2-carbonyl]-L-valinate (5.7 mg, 
7%) as white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.82 (d, J=8.5 Hz, 1H), 4.36 
(dd, J=8.5, 5.9 Hz, 1H), 4.28 - 4.34 (m, 2H), 3.66 - 3.70 (m, 3H), 3.66 - 3.75 (m, 4H), 2.75 - 
2.85 (m, 1H), 2.21 (dq, J=13.2, 6.7 Hz, 1H), 2.02 - 2.11 (m, 2H), 1.85 - 1.93 (m, 3H), 1.85 - 
1.93 (m, 2H), 1.85 - 1.94 (m, 3H), 0.90 - 0.95 (m, 3H), 0.92 (d, J=6.9 Hz, 3H). 13C NMR (500 
MHz, DMSO-d6) δ 172.6, 164.1, 147.2, 146.9, 134.8, 127.4, 70.1, 57.3, 52.3, 49.5, 34.0, 30.5, 
25.2, 24.8, 19.3, 18.4, 18.2. HRMS (pos. ESI): m/z calculated for C20H30N4O4 [M+H]+ 
391.2343, found 391.2344. 
Synthesis of RO6892033, 6-(3-tert-Butyl-1,2,4-oxadiazol-5-yl)-3-cyclopropyl-2-[(4-
fluorophenyl)methyl]pyridine.  
  
1,1′-Carbonyldiimidazole (13.4 mg, 83 µmol) was added to a solution of 5-cyclopropyl-6-(4-
fluorobenzyl)picolinic acid (CAS number 1415899-48-7; 15 mg, 55.3 µmol) in 
N,N‑dimethylformamide (643 μL). The mixture was stirred for 30 minutes at ambient 
temperature. N'-Hydroxypivalimidamide (CAS number 42956-75-2; 9.63 mg, 82.9 µmol) was 
added and the reaction mixture was stirred for 1 h at ambient temperature. The temperature 
was increased to 100 °C and stirring was continued for 72 h. The reaction mixture was purified 
by preparative HPLC and subsequent preparative thin layer chromatography (silica gel, 1.0 
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mm, heptane / ethyl acetate 3:1, elution with ethyl acetate) to give the title compound (6 mg, 
31%) as colorless liquid. 1H NMR (500 MHz, DMSO-d6) δ 8.01 (d, J=8.0 Hz, 1H), 7.58 (d, 
J=8.1 Hz, 1H), 7.27 (dd, J=8.6, 5.6 Hz, 2H), 7.11 (t, J=8.9 Hz, 2H), 4.40 (s, 2H), 2.02 - 2.12 
(m, 1H), 1.38 (s, 9H), 0.94 - 1.05 (m, 2H), 0.68 - 0.76 (m, 2H). 13C NMR (500 MHz, DMSO-d6) 
δ 178.1, 174.2, 161.1, 160.4, 141.7, 139.8, 135.3, 134.5, 130.7, 123.0, 115.5, 40.4, 32.6, 28.6, 
12.6, 9.0. HRMS (pos. ESI): m/z calculated for C21H22FN3O [M+H]+ 352.1826, found 352.1825. 
Synthesis of FMP7234690, FMP7234691, FMP7234694, FMP7234698 and FMP7234699. 
The synthesis of the 2,5,6-trisubstituted pyridine series (compounds FMP7234690, 
FMP7234691, FMP7234694, FMP7234698 and FMP7234699) commences with the synthesis 
of the key intermediates ethyl 2-amino-2-ethylpent-4-enoate (3) and 5-cyclopropyl-6-(4-
fluorobenzyl)picolinic acid (4) (Scheme 1). Starting from commercially available racemic 
amino butyric acid (1), classical Fischer esterification conditions, followed by imine formation 
using benzaldehyde under basic conditions, gave imine (2) in good 93% yield, over steps a 
and b. Lithium-assisted deprotonation/alkylation of imine (2) using LDA (lithium di‑isopropyl 
amide) and allylbromide, followed by imine deprotection under acidic conditions yielded key 
intermediate (3) in overall 96% yield. The synthesis of picolinic acid (4) have been described 
by Bissantz and collaborators56 and was synthesized as reported. Amide coupling conditions 
using key intermediates (3) and (4) gave amide (5) in moderate 56% yield. 
Brown‑hydroboration reaction in nearly quantitative yield (99%), followed by Mitsunobu 
reaction using thioacetic acid provided thioester (6) in 63% yield. Cleavage of the acetylthio 
group, followed by one-pot alkylation with the corresponding linker was achieved under strong 
basic conditions. Subsequent deprotection of the boc-group afforded amines (7 – 11) in 
moderate yields (46 – 56%). Final fluorophore coupling using 4-chloro-7-nitrobenzofurazan 
(NBD‑chloride) and cesium carbonate as base provided compounds FMP7234690, 
FMP7234691, FMP7234694, FMP7234698 and FMP7234699.  
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 




Scheme 1. Reagents and conditions: a) thionyl chloride, EtOH, 0 to 78 °C, 5 h; b) 
Benzaldehyde, Et3N, MgSO4, DCM, room temperature, 30 h (93%, over 2 steps); c) Allyl 
Bromide, LDA, THF, -78 °C to room temperature, 24 h; d) HCl aq., H2O, Et2O, 0 °C to room 
temperature, 15 h (96%, over 2 steps); e) 14, BOP-Cl, DIPEA, DCM, room temperature, 30 h 
(54%); f) (i) 9-BBN, THF, room temperature, 36 h; (ii) EtOH, room temperature, 30 min; then 
NaOH, H2O2, 0 °C, 1 h (99%, over 2 steps); g) thioacetic acid, DIAD, PPh3, THF, 0 °C, 2 h 
(64%); h) linker, EtONa, EtOH, -20 °C to room temperature, 18 h (46 – 56%); i) TFA:DCM 
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(9:1), 0 °C to room temperature, 2 h; j) 4-Chloro-7-nitrobenzofurazan, Cs2CO3, DMF, 0 °C to 
room temperature, 24 h (18 – 49%, over 2 steps). 
Ethyl 2-(benzylideneamino)butanoate (2): Thionyl chloride (3.5 mL, 47.9 mmol) was added 
dropwise to a solution of amino butyric acid 1 (CAS number 2835-81-6; 3.8 g, 36.9 mmol) in 
ethanol (40 mL), over a period of 5 min at 0 °C. The reaction mixture was stirred at 0 °C for 1 
additional hour. Afterwards, the resulting solution was refluxed (80 °C) for 4 h. The reaction 
mixture was cooled to room temperature and concentrated under reduced pressure to yield 
ethyl 2‑aminobutanoate as a colorless oil (4.8 g, quant.), used without further purification for 
the next step. Ethyl 2-aminobutanoate (4.8 g, 36.9 mmol) and dried magnesium sulfate (4.4 
g, 36.9 mmol) were stirred in anhydrous dichloromethane (DCM; 30 mL) at ambient 
temperature for 20 min. Afterwards, benzaldehyde (3.8 mL, 36.9 mmol) and triethylamine (9.5 
mL, 68.2 mmol) were added sequentially and dropwise. The resulting mixture was stirred for 
30 h at the same temperature then filtered and concentrated. The residue was dissolved in 
ether (8 mL) and water (8 mL) and the separated aqueous layer was extracted with ether. The 
combined ether solutions were washed with brine (8 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure to give the desired imine 2 as a clear oil (7.53 g, 93%). 
1H NMR (600 MHz, Chloroform-d) δ ppm 8.28 (s, 1H), 7.80 – 7.76 (m, 2H), 7.44 – 7.39 (m, 
3H), 4.25 – 4.17 (m, 2H), 3.87 (dd, J = 8.2, 5.5 Hz, 1H), 2.09 – 2.00 (m, 1H), 1.94 – 1.88 (m, 
1H), 1.27 (t, J = 7.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (150 MHz, Chloroform-d) δ 
ppm 172.3, 163.2, 135.9, 131.1, 128.7, 75.1, 61.0, 26.78, 14.34, 10.6. HRMS (pos. ESI‑TOF): 
m/z calculated for C13H17NO2 [M+H]+ 220.1259, found 220.1351.  
Ethyl 2-amino-2-ethylpent-4-enoate (3): To a solution of lithium diisopropylamine (LDA; 4.2 
mL, 8.4 mmol) in tetrahydrofuran (4 mL) cooled to –78 °C was added ethyl 2-
(benzylideneamino) butyrate 2 (1.2 g, 5.61 mmol) in tetrahydrofuran (4 mL), followed by the 
dropwise addition of allyl bromide (0.73 mL, 8.41 mmol). The mixture was stirred at room 
temperature for 24 h, and then concentrated under reduced pressure. The residue was then 
partitioned between ethyl acetate and water. The organic layer was separated, and the 
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aqueous phase was extracted with ethyl acetate (4x). The combined organic extracts were 
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. The 
crude residue was dissolved in diethyl ether (15 mL) and treated with hydrochloric acid (1 M, 
3.5 equiv., 21.9 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature 
and stirred for additional 15 h. The ether layer was separated, and the water phase extracted 
with dichloromethane (2x). The dichloromethane extracts were extracted with hydrochloric 
acid (0.2 M, 2x). The aqueous layers were combined and lyophilized to yield the corresponding 
amino ester hydrochloric salt (1.1 g, 96%), without the need of further purification steps. 1H 
NMR (300 MHz, Chloroform-d) δ ppm 5.74 – 5.60 (m, 1H), 5.21 – 5.05 (m, 2H), 4.15 (q, J = 
7.1 Hz, 2H), 2.53 (dd, J = 13.5, 6.4 Hz, 1H), 2.21 (dd, J = 13.5, 8.4 Hz, 1H), 1.84 – 1.66 (m, 
3H), 1.60 – 1.48 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, 
Chloroform-d) δ ppm 176.6, 132.8, 119.3, 119.2, 60.8, 43.8, 32.7, 14.2, 8.1. HRMS (pos. 
ESI‑TOF): m/z calculated for C9H17NO2 [M+H]+ 172.1259, found 172.1337. 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethylpent-4-enoate (5): To a 
solution of 5-cyclopropyl-6-(4-fluorobenzyl)picolinic acid 456 (300.0 mg, 1.01 mmol) in 
dichloromethane (7 mL) at room temperature were added DIPEA (0.87 mL, 5.05 mmol), bis-
(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl; 310.6 mg, 1.22 mmol). The mixture was 
stirred at room temperature for 1 h before amino ester 3 (172.9 mg, 1.01 mmol) in 
dichloromethane (3 mL) was added. The mixture was stirred at room temperature for 24 h, 
diluted with dichloromethane (10 mL) and washed with hydrochloric acid (0.2 M, 3x) and brine 
(1x). The organic layer was dried (MgSO4) and concentrated under reduced pressure. 
Purification was performed by flash chromatography (silica gel, 4 g, 10% ethyl acetate in 
cyclohexane) to yield amide 5 as a yellow oil (238.8 mg, 56%). 1H NMR (300 MHz, Chloroform-
d) δ ppm 8.95 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.31 – 7.20 (m, 2H), 
6.97 (t, J = 8.6 Hz, 2H), 5.72 – 5.58 (m, 1H), 5.16 – 4.96 (m, 2H), 4.43 – 4.22 (m, 4H), 3.30 
(dd, J = 14.0, 6.9 Hz, 1H), 2.69 – 2.49 (m, 2H), 2.00 – 1.88 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H), 
1.05 – 0.96 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H), 0.83 – 0.65 (m, 2H). 13C NMR (75 MHz, 
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Chloroform-d) δ ppm 173.1, 164.3, 163.0, 159.8, 158.3, 146.7, 139.7, 134.6, 134.5, 132.6, 
130.4, 130.3, 119.6, 118.4, 115.2, 114.9, 64.8, 61.5, 40.6, 39.2, 28.1, 14.2, 12.6, 8.3, 7.7. 
HRMS (pos. ESI‑TOF): m/z calculated for C25H29FN2O3 [M+Na]+ 447.2162, found 447.2083.  
Ethyl 5-(acetylthio)-2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethylpentano-
ate (6): To a solution of compound 5 (238.8 mg, 0.56 mmol) in tetrahydrofuran (2.0 mL) at 
room temperature and nitrogen atmosphere were added 9‑borabicyclo[3.3.1]nonane (9-BBN; 
0.5 M in tetrahydrofuran, 1.7 mL, 0.84 mmol). The mixture was stirred at room temperature for 
36 h, followed by quenching the excess of 9‑BBN with ethanol (0.11 mL, 1.96 mmol). The 
mixture was stirred at room temperature for 30 min. followed by the concurrent dropwise ad-
dition of sodium hydroxide aq. sol. (2 M, 2.2 mL) and hydrogen peroxide aq. sol. (30%, 2.2 
mL) at 0 °C. After complete addition, stirring was continued at the same temperature for 
additional 1 h. The solution was extracted with ether (3x). Subsequent purification by flash 
chromatography (silica gel, 15 g, 50% ethyl acetate in cyclohexane) was performed to give 
intermediate ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-hydroxy-
pentanoate as a colorless solid (245.6 mg, 99%). 1H NMR (600 MHz, Chloroform-d) δ ppm 
9.02 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.27 – 7.24 (m, 3H), 6.99 – 6.94 (m, 2H), 4.41 (s, 2H), 
4.36 (s, 2H), 4.33 – 4.27 (m, 2H), 3.62 – 3.55 (m, 1H), 2.65 – 2.60 (m, 1H), 2.56 – 2.52 (m, 
1H), 2.05 – 1.95 (m, 1H), 1.95 – 1.85 (m, 2H), 1.55 – 1.49 (m, 1H), 1.43 – 1.35 (m, 1H), 1.33 
(td, J = 7.1, 1.8 Hz, 3H), 1.02 – 0.98 (m, 2H), 0.77 (td, J = 7.4, 2.6 Hz, 3H), 0.67 – 0.65 (m, 
2H). 13C NMR (151 MHz, CDCl3) δ ppm 173.8, 163.6, 160.9, 158.6, 146.9, 140.0, 134.8, 130.5, 
130.5, 119.9, 115.3, 115.2, 65.1, 62.8, 61.9, 40.8, 31.5, 28.9, 27.8, 14.4, 14.4, 12.9, 8.6, 7.9.  
HRMS (pos. ESI‑TOF): m/z calculated for C25H31FN2O4 [M+Na]+ 443.2268, found 443.2337. 
Diisopropyl azodicarboxylate (DIAD; 0.045 mL, 0.23 mmol) in anhydrous tetrahydrofuran (0.2 
mL) was added dropwise to a stirred solution of triphenylphosphine (60.3 mg, 0.23 mmol) in 
anhydrous tetrahydrofuran (1.0 mL) at 0 °C under nitrogen atmosphere. The mixture was 
stirred at this temperature for 30 min, until formation of a white precipitate of Mitsunobu 
betaine, and a solution of thioacetic acid (0.02 mL, 0.23 mmol) and ethyl 2-(5-cyclopropyl-6-
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(4-fluorobenzyl)picolinamido)-2-ethyl-5-hydroxypentanoate (51.0 mg, 0.11 mmol) in 
anhydrous tetrahydrofuran (1.5 mL) was added slowly. The reaction was stirred at 0 °C for 
1 h, allowed to reach room temperature, and stirred for additional 1 h. Afterwards, the reaction 
mixture was concentrated, and the residue taken up into a mixture of diethyl ether and 
cyclohexane (1:1) and triturated at 0 °C. The resulting white solid was filtered off and washed 
with diethyl ether and cyclohexane (1:1) mixture. The filtrate was evaporated under reduced 
pressure, and the residue purified by flash chromatography (silica gel, 4 g, 10% ethyl acetate 
in cyclohexane) to yield compound 6 as a colorless oil (35.6 mg, 64%). 1H NMR (300 MHz, 
Chloroform-d) δ ppm 8.99 (s, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.30 – 
7.19 (m, 3H), 7.02 – 6.91 (m, 2H), 4.39 – 4.23 (m, 4H), 2.88 – 2.76 (m, 2H), 2.69 – 2.45 (m, 
2H), 2.28 (s, 3H), 2.01 – 1.81 (m, 3H), 1.64 – 1.49 (m, 1H), 1.43 – 1.23 (m, 5H), 1.04 – 0.95 
(m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.70 – 0.62 (m, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 195.8, 
173.6, 163.5, 160.0, 158.5, 146.8, 140.0, 134.8, 134.8, 130.6, 130.5, 119.8, 115.4, 115.1, 
65.0, 61.9, 40.8, 34.4, 30.7, 29.1, 28.6, 24.7, 24.7, 14.4, 12.8, 8.5, 7.9, 7.9. HRMS (pos. 
ESI‑TOF): m/z calculated for C27H33FN2O4S [M+Na]+ 523.2058, found 523.2169. 
General Procedure for the linker synthesis: N-Boc PEG 2–5, or N-Boc hydroxyhexyl (1.0 
equiv.) was dissolved in dichloromethane (1.5 mL) and treated with p-toluenesulfonyl chloride 
(3.0 equiv.) and pyridine (5.0 equiv.) at 0 °C. The reaction was allowed to warm to room 
temperature, and then stirred at 40 °C for 12 h. The mixture was diluted with dichloromethane, 
and washed with hydrochloric acid (0.2 M, 5 mL), water (5 mL), and brine (5 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (silica gel, 4 g, 15 to 30% ethyl acetate in cyclohexane), giving a colorless 
oil. 
2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate was obtained 
in quantitative yield (86.2 mg) starting from tert-butyl (2-(2-hydroxyethoxy)ethyl)carbamate 
(BocNH-PEG2, 50.0 mg, 0.24 mmol). 1H NMR (300 MHz, Chloroform-d) δ ppm 7.83 (d, J = 
8.2 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 4.82 (s, 1H), 4.18 (dd, J = 5.7, 3.6 Hz, 2H), 3.65 (dd, J 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.09.375162doi: bioRxiv preprint 
50 
 
= 5.5, 3.8 Hz, 2H), 3.47 (t, J = 5.1 Hz, 2H), 3.26 (q, J = 5.2 Hz, 2H), 2.47 (s, 3H), 1.47 (s, 9H). 
13C NMR (75 MHz, Chloroform-d) δ ppm 155.9, 144.9, 133.0, 129.8, 128.0, 79.4, 70.4, 69.1, 
68.4, 40.2, 28.4, 21.7. HRMS (pos. ESI‑TOF): m/z calculated for C16H25NO6S [M+Na]+ 
382.1413, found 382.1303. 
2,2-Dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate was 
obtained in quantitative yield (114.1 mg) starting from tert-butyl (2-(2-(2-hydroxy-
ethoxy)ethoxy)ethyl)carbamate (BocNH-PEG3, 60.0 mg, 0.24 mmol). 1H NMR (300 MHz, 
Chloroform-d) δ ppm 7.81 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 4.96 (bs, 1H), 4.18 (t, 
J = 4.8 Hz, 2H), 3.71 (t, J = 4.8 Hz, 2H), 3.62 – 3.47 (m, 6H), 3.33 – 3.28 (m, 2H), 2.46 (s, 3H), 
1.45 (s, 9H). 13C NMR (75 MHz, Chloroform-d) δ ppm 156.0, 144.9, 133.0, 129.8, 128.0, 79.3, 
70.71, 70.3, 70.2, 69.2, 68.7, 40.3, 28.4, 21.7. HRMS (pos. ESI‑TOF): m/z calculated for 
C18H29NO7S [M+Na]+ 426.1658, found 426.1548. 
2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfo-
nate was obtained in 66% yield (71.0 mg) starting from tert-butyl (2-(2-(2-(2-hydroxy-
ethoxy)ethoxy)ethoxy)ethyl)carbamate (BocNH-PEG4, 70.0 mg, 0.24 mmol). 1H NMR (300 
MHz, Chloroform-d) δ ppm 7.82 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 5.02 (bs, 1H), 
4.23 – 4.14 (m, 2H), 3.75 – 3.67 (m, 2H), 3.62 (s, 8H), 3.56 – 3.53 (m, 2H), 3.34 – 3.29 (m, 
2H), 2.47 (s, 3H), 1.45 (s, 9H). 13C NMR (75 MHz, Chloroform-d) δ ppm 156.0, 144.8, 133.0, 
129.8, 128.0, 79.2, 70.8, 70.6, 70.5, 70.2, 69.2, 68.7, 40.5, 28.4, 21.7. HRMS (pos. ESI‑TOF): 
m/z calculated for C20H33NO8S [M+Na]+ 465.1941, found 465.2275.  
2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4‑methylbenzenesul-
fonate was obtained in 94% yield (111.0 mg) starting from tert-butyl (14-hydroxy-3,6,9,12-
tetraoxatetradecyl)carbamate (BocNH-PEG5, 81.0 mg, 0.24 mmol).  1H NMR (300 MHz, 
Chloroform-d) δ ppm 7.80 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 5.04 (bs, 1H), 4.21 – 
4.12 (m, 2H), 3.71 – 3.67 (m, 2H), 3.59 – 3.66 (m, 12H), 3.57 – 3.51 (m, 2H), 3.32 – 3.29 (m, 
2H), 2.45 (s, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, Chloroform-d) δ ppm 156.0, 144.8, 133.0, 
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129.8, 128.0, 79.2, 70.8,70.6, 70.5, 70.2, 69.2, 68.7, 40.4, 28.4, 21.7. HRMS (pos. ESI‑TOF): 
m/z calculated for C22H37NO9S [M+Na]+ 530.2215, found 530.1841.  
6-((tert-butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate was obtained in 42% 
yield (37.8 mg) starting from tert-butyl (6-hydroxyhexyl)carbamate (BocNH-hydroxyhexyl, 52.0 
mg, 0.24 mmol).  1H NMR (300 MHz, Chloroform-d) δ ppm 7.80 (d, J = 8.2 Hz, 2H), 7.37 (d, J 
= 8.1 Hz, 2H), 4.52 (s, 1H), 4.03 (t, J = 6.4 Hz, 2H), 3.11 – 3.05 (m, 2H), 2.47 (s, 3H), 1.72 – 
1.58 (m, 2H), 1.45 (s, 11H), 1.37 – 1.23 (m, 4H). 13C NMR (75 MHz, Chloroform-d) δ ppm 
156.0, 144.7, 133.1, 129.8, 127.9, 79.1, 70.5, 40.4, 29.9, 28.7, 28.4, 26.1, 25.1, 22.0. HRMS 
(pos. ESI‑TOF): m/z calculated for C18H29NO5S [M+Na]+ 394.1794, found 394.1685. 
General procedure for synthesis of intermediates 7 – 11: Thioderivative 6 (1.0 equiv.) and 
the corresponding tosyl linker (1.8 equiv.) were added to oxygen-free absol. ethanol (2 mL) 
under nitrogen atmosphere. The suspension was cooled to -20 °C, sodium ethoxyde (3.0 
equiv.) was added along with catalytic amounts of potassium iodide (0.3 equiv.), and the 
mixture was allowed to warm up slowly to room temperature. The resulting solution was stirred 
for 20 h. The reaction mixture was concentrated under reduced pressure, and the resulting 
residue was dissolved in acetonitrile and water (1:1) and purified on reverse-phase preparative 
HPLC (30-90% acetonitrile in water with 0.1% trifluoroacetic acid (TFA), 32 min). The fractions 
containing the product were combined and lyophilized to yield the desired product. 
Ethyl 15-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-15-ethyl-2,2-dimethyl-4-oxo-
3,8-dioxa-11-thia-5-azahexadecan-16-oate (7) was obtained in 50% yield (16.2 mg) starting 
from 2‑(2-((tert-butoxycarbonyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (32.3 mg, 
0.09 mmol). 1H NMR (300 MHz, Chloroform-d) δ ppm 9.02 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 
7.39 (d, J = 8.0 Hz, 1H), 7.30 – 7.21 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 4.95 (bs, 1H), 4.46 – 
4.19 (m, 4H), 3.56 – 3.43 (m, 4H), 3.29 – 3.24 (m, 2H), 2.67 – 2.47 (m, 6H), 2.06 – 1.82 (m, 
4H), 1.64 – 1.56 (m, 1H), 1.43 (s, 9H), 1.33 (t, J = 7.1 Hz, 3H), 1.05 – 0.94 (m, 2H), 0.76 (t, J 
= 7.4 Hz, 3H), 0.79 – 0.64 (m, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.5, 163.2, 
160.0, 158.5, 156.1, 146.8, 140.1, 134.8, 130.6, 130.5, 119.8, 115.4, 115.1, 79.4, 70.7, 70.0, 
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65.1, 61.9, 40.8, 40.5, 34.5, 32.5, 31.6, 28.6, 28.6, 24.8, 14.5, 12.8, 8.6, 7.9. HRMS (pos. 
ESI‑TOF): m/z calculated for C34H48FN3O6S [M+Na]+ 668.3278, found 668.3154. 
Ethyl 18-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-18-ethyl-2,2-dimethyl-4-oxo-
3,8,11-trioxa-14-thia-5-azanonadecan-19-oate (8) was obtained in 49% yield (13.4 mg) 
starting from 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl 4-methylbenzenesulfonate 
(29.1 mg, 0.07 mmol). 1H NMR (300 MHz, Chloroform-d) δ ppm 9.01 (s, 1H), 7.89 (d, J = 7.9 
Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.30 – 7.20 (m, 2H), 7.03 – 6.92 (m, 2H), 5.02 (bs, 1H), 4.40 
– 4.23 (m, 4H), 3.62 – 3.45 (m, 8H), 3.34 – 3.30 (m, 2H), 2.68 – 2.44 (m, 6H), 2.05 – 1.82 (m, 
3H), 1.64 – 1.55 (m, 1H), 1.43 (s, 9H), 1.35 – 1.18 (m, 4H), 1.03 – 0.97 (m, 2H), 0.76 (t, J = 
7.4 Hz, 3H), 0.72 – 0.62 (m, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 173.7, 163.5, 163.2, 158.5, 
156.1, 146.8, 140.0, 134.8, 130.6, 130.5, 119.8, 115.4, 115.1, 79.3, 71.0, 70.4, 70.3, 65.1, 
61.9, 40.9, 40.4, 34.5, 32.5, 31.5, 28.6, 24.9, 14.5, 12.9, 8.6, 7.9. HRMS (pos. ESI‑TOF): m/z 
calculated for C36H52FN3O7S [M+Na]+ 712.3462, found 712.3346.  
Ethyl 21-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-21-ethyl-2,2-dimethyl-4-oxo-
3,8,11,14-tetraoxa-17-thia-5-azadocosan-22-oate (9) was obtained in 52% yield (19.0 mg) 
starting from 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4‑methylbenzene-
sulfonate (40.3 mg, 0.09 mmol). 1H NMR (300 MHz, Chloroform-d) δ ppm 9.01 (s, 1H), 7.89 
(d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.30 – 7.21 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 5.03 
(bs, 1H), 4.43 – 4.21 (m, 4H), 3.66 – 3.68 (m, 12H), 3.33 – 3.27 (m, 2H), 2.69 – 2.44 (m, 6H), 
2.08 – 1.76 (m, 4H), 1.64 – 1.55 (m, 1H), 1.43 (s, 9H), 1.33 (t, J = 7.1 Hz, 3H), 1.03 – 0.96 (m, 
2H), 0.76 (t, J = 7.4 Hz, 3H), 0.78 – 0.64 (m, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 173.7, 
163.5, 163.2, 160.0, 158.5, 156.1, 146.8, 134.8, 130.6, 130.5, 119.8, 115.4, 115.1, 79.3, 71.0, 
70.7, 70.4, 70.4, 65.1, 61.9, 40.8, 34.5, 32.5, 31.5, 28.6, 24.9, 14.5, 12.8, 8.6, 7.9. HRMS (pos. 
ESI‑TOF): m/z calculated for C38H56FN3O8S [M+Na]+ 756.3792, found 756.3682. 
Ethyl 24-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-24-ethyl-2,2-dimethyl-4-oxo-
3,8,11,14,17-pentaoxa-20-thia-5-azapentacosan-25-oate (10) was obtained in 56% yield 
(21.8 mg) starting from 2,2‑dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-
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methylbenzenesulfonate (44.2 mg, 0.09 mmol). 1H NMR (300 MHz, Chloroform-d) δ ppm 9.01 
(s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38(d, J = 8.0 Hz, 1H), 7.29 – 7.21 (m, 2H), 6.97 (t, J = 8.6 
Hz, 2H), 5.04 (bs, 1H), 4.39 – 4.24 (m, 4H), 3.68 – 3.47 (m, 16H), 3.35 – 3.30 (m, 2H), 2.69 – 
2.42 (m, 6H), 2.08 – 1.80 (m, 4H), 1.65 – 1.51 (m, 1H), 1.43 (s, 9H), 1.33 (t, J = 7.1 Hz, 3H), 
1.04 – 0.95 (m, 2H), 0.76 (t, J = 7.4 Hz, 3H), 0.78 – 0.64 (m, 2H). 13C NMR (75 MHz, CDCl3) 
δ ppm 173.7, 163.4, 160.0, 158.5, 156.1, 146.8, 140.1, 134.9, 130.6, 130.5, 119.9, 115.4, 
115.1, 79.3, 70.7, 70.7, 70.7, 70.4, 70.3, 65.1, 61.9, 40.8, 40.5, 34.5, 32.5, 31.5, 28.6, 24.8, 
14.5, 12.8, 8.6, 7.9. HRMS (pos. ESI‑TOF): m/z calculated for C40H60FN3O9S [M+Na]+ 
800.4078, found 800.3942. 
Ethyl 5-((6-((tert-butoxycarbonyl)amino)hexyl)thio)-2-(5-cyclopropyl-6-(4-fluorobenzyl) 
picolinamido)-2-ethylpentanoate (11) was obtained in 51% yield (16.9 mg) starting from 6-
((tert-butoxycarbonyl)amino)hexyl 4-methylbenzenesulfonate (33.4 mg, 0.09 mmol). 1H NMR 
(300 MHz, Chloroform-d) δ ppm 9.02 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 
7.32 – 7.19 (m, 2H), 6.96 (t, J = 8.6 Hz, 2H), 4.53 (s, 1H), 4.38 – 4.24 (m, 4H), 3.11 – 3.04 (m, 
2H), 2.67 – 2.37 (m, 6H), 2.07 – 1.84 (m, 3H), 1.60 – 1.24 (m, 22H), 1.06 – 0.94 (m, 2H), 0.76 
(t, J = 7.4 Hz, 3H), 0.79 – 0.63 (m, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 173.8, 163.5, 160.0, 
158.3, 156.1, 146.8, 140.0, 134.8, 130.6, 130.5, 119.8, 115.4, 115.1, 79.2, 65.1, 61.9, 40.8, 
34.6, 32.1, 32.0, 30.1, 29.6, 28.6, 28.6, 26.5, 24.7, 14.4, 12.8, 8.6, 7.9, 7.9. HRMS (pos. 
ESI‑TOF): m/z calculated for C36H52FN3O5S [M+Na]+ 680.3664, found 680.3516. 
General procedure for synthesis of FMP7234690, FMP7234691, FMP7234694, 
FMP7234698 and FMP7234699: TFA (0.25 mL) was added dropwise to a stirring solution of 
the corresponding Boc-protected intermediate 7 – 11 (1.0 equiv.) in dichloromethane (2.25 
mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, and at room temperature for 
additional 1 h. Afterwards, the mixture was concentrated under reduced pressure, and the 
residue re-suspended in ethyl acetate (5 mL). The solvent was removed by rotary evaporation. 
This process was repeated 3 times to remove TFA traces. The removal of the tert-
butyloxycarbonyl group was quantitative as observed by TLC (50% ethyl acetate in 
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cyclohexane). The product was obtained as its corresponding TFA salt and was used for the 
next step without further purification. To a solution of free amino intermediate (1.0 equiv.) and 
Cs2CO3 (5.0 equiv.) in dimethylformamide (2 mL) at room temperature 4-chloro-7-
nitrobenzofurazan (NBD-Cl, CAS number 10199-89-0; 1.0 equiv.) was added. The reaction 
was stirred at room temperature for 24 h. The reaction mixture was concentrated under 
reduced pressure, and the obtained residue was diluted with a mixture of acetonitrile and water 
(1:1) and purified on reverse-phase preparative HPLC (30 to 90% acetonitrile in water with 
0.1% TFA, 32 min). The fractions containing the product were combined and lyophilized to 
yield the desired product. 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-((2-(2-((7-nitrobenzo-
[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)ethyl)thio)pentanoate (FMP7234690) was obtained 
in 49% yield (4.5 mg) starting from Boc-protected 7 (10.0 mg, 0.02 mmol). 1H NMR (cryo 600 
MHz, DMSO-d6) δ ppm 9.41 (s, 1H), 8.69 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 7.74 (d, J = 8.0 Hz, 
1H), 7.51 (d, J = 8.1 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.11 – 7.06 (m, 2H), 6.44 (d, J = 9.0 Hz, 
1H), 4.34 (s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.70 – 3.63 (m, 4H), 3.51 (t, J = 6.7 Hz, 2H), 2.54 
(t, J = 6.7 Hz, 2H), 2.46 – 2.41 (m, 2H), 2.34 – 2.24 (m, 2H), 2.09 – 2.05 (m, 1H), 1.88 – 1.75 
(m, 2H), 1.38 – 1.32 (m, 2H), 1.20 (t, J = 7.1 Hz, 4H), 1.10 – 0.96 (m, 2H), 0.70 – 0.64 (m, 4H). 
13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.2, 158.0, 146.1, 
145.3, 144.4, 144.1, 140.3, 137.8, 135.0, 134.4, 130.7, 120.9, 119.3, 114.9, 99.5, 70.2, 67.6, 
63.6, 61.4, 43.3, 33.4, 31.3, 30.5, 26.6, 23.9, 14.4, 12.1, 8.2, 8.1, 8.0.  HRMS (pos. ESI‑TOF): 
m/z calculated for C35H41FN6O7S [M+Na]+ 731.2760, found 731.2646. 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-((2-(2-(2-((7-nitro-
benzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)ethoxy)ethyl)thio)pentanoate 
(FMP7234691) was obtained in 26% yield (2.5 mg) starting from Boc-protected 8 (10.0 mg, 
0.01 mmol). 1H NMR (cryo 600 MHz, DMSO-d6) δ ppm 9.43 (s, 1H), 8.70 (s, 1H), 8.49 (d, J = 
9.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.11 – 7.06 
(m, 2H), 6.54 (d, J = 9.0 Hz, 1H), 4.34 (s, 2H), 4.31 (q, J = 7.1 Hz, 2H), 3.69 (t, J = 5.3 Hz, 
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2H), 3.49 – 3.51 (m, 3H), 3.43 – 3.39 (m, 3H), 2.48 (t, J = 6.7 Hz, 2H), 2.40 – 2.45 (m, 2H), 
2.35 – 2.26 (m, 3H), 2.10 – 2.04 (m, 2H), 1.92 – 1.77 (m, 3H), 1.38 – 1.33 (m, 2H), 1.21 (t, J 
= 7.1 Hz, 3H), 1.01 – 0.96 (m, 2H), 0.70 – 0.65 (m, 4H). 13C NMR (cryo 151 MHz, DMSO-d6) 
δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.3, 144.4, 144.1, 140.3, 137.8, 135.0, 
134.4, 130.7, 130.6, 120.8, 119.3, 115.1, 114.9, 99.5, 70.2, 69.8, 69.4, 63.6, 61.4, 43.4, 33.4, 
31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.1, 8.0. HRMS (pos. ESI‑TOF): m/z calculated for 
C37H45FN6O8S [M+Na]+ 775.3027, found 775.2911. 
Ethyl 16-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-16-ethyl-1-((7-nitrobenzo[c]-
[1,2,5]oxadiazol-4-yl)amino)-3,6,9-trioxa-12-thiaheptadecan-17-oate (FMP7234694) was 
obtained in 49% yield (3.1 mg) starting from Boc-protected 9 (10.0 mg, 0.01 mmol). 1H NMR 
(cryo 600 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 8.70 (s, 1H), 8.50 (d, J = 8.8 Hz, 1H), 7.75 (d, 
J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.34 – 7.30 (m, 2H), 7.12 – 7.06 (m, 2H), 6.47 (d, J 
= 9.0 Hz, 1H), 4.34 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.70 (t, J = 5.3 Hz, 2H), 3.70 – 3.62 (m, 
2H), 3.55 – 3.53 (m, 2H), 3.49 – 3.47 (m, 3H), 3.41 – 3.39 (m, 5H), 3.37 – 3.34 (m, 2H), 2.45 
(td, J = 7.1, 3.0 Hz, 2H), 2.37 – 2.26 (m, 2H), 2.10 – 2.05 (m, 2H), 1.92 – 1.87 (m, 1H), 1.84 – 
1.79 (m, 1H), 1.41 – 1.33 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 1.01 – 0.97 (m, 2H), 0.70 – 0.65 
(m, 4H). 13C NMR (cryo 151 MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 
145.3, 144.1, 140.3, 137.8, 135.0, 134.4, 130.7, 130.6, 120.8, 119.3, 115.1, 114.9, 99.5, 70.1, 
69.8, 69.7, 69.4, 68.0, 63.6, 61.4, 43.4, 33.4, 31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.1, 8.0.  HRMS 
(pos. ESI‑TOF): m/z calculated for C39H49FN6O9S [M+Na]+ 819.3277, found 819.3161.  
Ethyl 19-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-19-ethyl-1-((7-nitrobenzo[c]-
[1,2,5]oxadiazol-4-yl)amino)-3,6,9,12-tetraoxa-15-thiaicosan-20-oate (FMP7234698) was 
obtained in 23% yield (2.7 mg) starting from Boc-protected 10 (14.0 mg, 0.02 mmol). 1H NMR 
(cryo 600 MHz, DMSO-d6) δ ppm 9.45 (s, 1H), 8.71 (s, 1H), 8.50 (d, J = 9.0 Hz, 1H), 7.75 (d, 
J = 8.0 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.12 – 7.07 (m, 2H), 6.47 (d, J 
= 9.0 Hz, 1H), 4.34 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.70 (t, J = 5.3 Hz, 1H), 3.56 – 3.54 (m, 
2H), 3.50 – 3.48 (m, 2H), 3.46 – 3.40 (m, 16H), 3.38 – 3.36 (m, 2H), 2.47 – 2.44 (m, 1H), 2.37 
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– 2.27 (m, 2H), 2.10 – 2.06 (m, 1H), 1.93 – 1.97 (m, 1H), 1.85 – 1.79 (m, 1H), 1.41 – 1.33 (m, 
1H), 122 (t, J = 7.1 Hz, 3H), 1.03 – 0.95 (m, 2H), 0.72 – 0.64 (m, 4H). 13C NMR (cryo 151 MHz, 
DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.3, 144.4, 144.1, 140.3, 137.8, 
135.0, 134.4, 130.7, 130.6, 120.8, 119.3, 115.0, 114.9, 99.5, 70.2, 69.8, 69.7, 69.7, 69.4, 68.0, 
63.6, 61.4, 60.2, 43.4, 33.4, 31.3, 30.4, 27.6, 23.9, 14.1, 12.1, 8.2, 8.0. HRMS (pos. ESI‑TOF): 
m/z calculated for C41H53FN6O10S [M+Na]+ 841.3595, found 841.3658. 
Ethyl 2-(5-cyclopropyl-6-(4-fluorobenzyl)picolinamido)-2-ethyl-5-((6-((7-nitrobenzo[c]-
[1,2,5]oxadiazol-4-yl)amino)hexyl)thio)pentanoate (FMP7234699) was obtained in 18% 
yield (1.6 mg) starting from Boc-protected 11 (11.0 mg, 0.02 mmol). 1H NMR (cryo 600 MHz, 
DMSO-d6) δ ppm 9.52 (t, J = 5.7 Hz, 1H), 8.72 (s, 1H), 8.50 (d, J = 8.9 Hz, 1H), 7.75 (d, J = 
8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.35 – 7.31 (m, 2H), 7.11 – 7.06 (m, 2H), 6.38 (d, J = 9.0 
Hz, 1H), 4.34 (d, J = 3.5 Hz, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.42 (q, J = 6.8, 6.3 Hz, 2H), 2.40 
(t, J = 7.1 Hz, 2H), 2.37 – 2.27 (m, 4H), 2.10 – 2.06 (m, 1H), 1.93 – 1.78 (m, 3H), 1.59 – 1.64 
(m, 2H), 1.44 – 1.20 (m, 11H), 1.02 – 0.96 (m, 2H), 0.70 – 0.65 (m, 4H). 13C NMR (cryo 151 
MHz, DMSO-d6) δ ppm 172.8, 162.3, 161.6, 160.0, 158.0, 145.8, 145.2, 144.4, 144.1, 140.3, 
138.0, 135.0, 134.4, 130.7, 130.6, 120.5, 119.3, 115.0, 114.9, 99.1, 63.6, 61.4, 43.3, 33.4, 
30.8, 30.7, 28.9, 27.8, 27.7, 27.5, 25.9, 23.7, 14.1, 12.1, 8.2, 8.1. HRMS (pos. ESI‑TOF): m/z 
calculated for C37H45FN6O6S [M+Na]+ 743.3244, found 743.3021. 
In vitro pharmacology. Human CB2, mouse CB2 and human CB1 ligand binding. 
Radioligand binding assays were performed with membranes prepared from cells expressing 
human CB2 or CB1 or mouse CB2 receptor using [3H]-CP55940 (Perkin Elmer) as a 
radioligand. Ki values were calculated from a single experiment using triplicates of ten different 
compound concentrations73. Human CB2, mouse CB2 and human CB1 cAMP assay. cAMP 
assays were performed using CHO cells stably expressing human CB2 or CB1 or mouse CB2, 
as previously described73. Efficacies are expressed as percentage relative to 10 μM CP55940. 
EC50 values are the average of determinations (n=1) performed in triplicate. Human CB2, 
mouse CB2 and human CB1 β‑arrestin assay. PathHunter β‑arrestin recruitment assay was 
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performed using the PathHunter hCB1_bgal, hCB2_bgal or mCB2_bgal CHOK1 β‑arrestin 
recruitment assay kit according to the manufacturer’s protocol as previously described38. 
Early ADME profile. Kinetic solubility (LYSA – lyophilisation solubility assay). The 
solubility of a test compound was measured in phosphate buffer at pH 6.5 from evaporated 
DMSO compound stock solution as previously described62. Passive membrane permeability 
(PAMPA). PAMPA (Parallel Artificial Membrane Permeability Assay) is a method which 
determines the permeability of substances from a donor compartment, through a lipid-infused 
artificial membrane, into an acceptor compartment. Read‑out is a permeation coefficient Peff 
well as test compound concentrations in donor, membrane and acceptor compartments63. 
Microsomal clearance. For human or mice, pooled commercially available microsome 
preparations from liver tissues are used74. For human, ultra-pooled (150 mixed gender donors) 
liver microsomes are purchased to account for the biological variance in vivo. For the 
microsome incubations, 96 deep well plates are applied, which are incubated at 37 °C on a 
TECAN (Tecan Group Ltd, Switzerland) equipped with Te-Shake shakers and a warming 
device (Tecan Group Ltd, Switzerland). The incubation buffer is 0.1 M phosphate buffer at pH 
7.4. The NADPH regenerating system consists of 30 mM glucose-6-phosphate disodium salt 
hydrate; 10 mM NADP; 30 mM mgCl2 x 6 H2O and 5 mg/mL glucose-6-phosphate 
dehydrogenase (Roche Diagnostics) in 0.1 M potassium phosphate buffer pH 7.4. Log peak 
area ratios (test compound peak area / internal standard peak area) are plotted against 
incubation time using a linear fit. The calculated slope is used to determine the intrinsic 
clearance: Clint (µL/min/mg protein) = -slope (min-1) * 1000 / [protein concentration (mg/mL)]. 
Hepatocyte clearance. For animals, hepatocyte suspension cultures are either freshly 
prepared by liver perfusion studies or prepared from cryopreserved hepatocyte batches. For 
human, commercially available, pooled (5-20 donors), cryopreserved human hepatocytes 
from non-transplantable liver tissues are mainly used75. For the suspension cultures, Nunc 
U96 PP-0.5 mL (Nunc Natural, 267245) plates are used, which are incubated in a Thermo 
Forma incubator from Fischer Scientific (Wohlen, Switzerland) equipped with shakers from 
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Variomag® Teleshake shakers (Sterico, Wangen, Switzerland) for maintaining cell dispersion. 
The cell culture medium is William’s media supplemented with Glutamine, antibiotics, insulin, 
dexamethasone and 10% FCS. Incubations of a test compound at 1 M test concentration in 
suspension cultures of 1x106 cells/mL (~1 mg/mL protein concentration) are performed in 96 
well plates and shaken at 900 rpm for up to 2 h in a 5% CO2 atmosphere and 37 °C. After 3, 
6, 10, 20, 40, 60 and 120 minutes 100 µL cell suspension in each well is quenched with 200 
µL methanol containing an internal standard. Samples are then cooled and centrifuged before 
analysis by LC-MS/MS. Log peak area ratios (test compound peak area / internal standard 
peak area) or concentrations are plotted against incubation time and a linear fit made to the 
data with emphasis upon the initial rate of compound disappearance. The slope of the fit is 
then used to calculate the intrinsic clearance: Clint (µL/min/1x106 cells) = -slope (min-1) * 
1000 / [1x106 cells]. Plasma protein binding. Pooled and frozen plasma from selected 
species were obtained from commercial suppliers 76,77. The Teflon equilibrium dialysis plate 
(96-well, 150 L, half-cell capacity) and cellulose membranes (12–14 kDa molecular weight 
cut-off) were purchased from HT-Dialysis (Gales Ferry, Connecticut). Both biological matrix 
and phosphate buffer pH are adjusted to 7.4 on the day of the experiment. The reference 
substance is diazepam. The determination of unbound compound is performed using a 96-
well format equilibrium dialysis device with a molecular weight cut-off membrane of 12 to 14 
kDa. The equilibrium dialysis device itself is made of Teflon to minimize non-specific binding 
of the test substance. Compounds are tested in cassettes of 2-5 with an initial total 
concentration of 1000 nM, one of the cassette compounds being the positive control 
diazepam. Equal volumes of matrix samples containing substances and blank dialysis buffer 
(Soerensen buffer at pH 7.4) are loaded into the opposite compartments of each well. The 
dialysis block is sealed and kept for 5 h at a temperature of 37 °C and 5% CO2 environment 
in an incubator. After this time, equilibrium will have been reached for most small molecule 
compounds with a molecular weight of < 600. The seal is then removed and matrix and buffer 
from each dialysis is prepared for analysis by LC-MS/MS. All protein binding determinations 
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are performed in triplicates. The integrity of membranes is tested in the HTDialysis device by 
determining the unbound fraction values for the positive control diazepam in each well. At 
equilibrium, the unbound drug concentration in the biological matrix compartment of the 
equilibrium dialysis apparatus is the same as the concentration of the compound in the buffer 
compartment. Thus, the percent unbound fraction (fu) can be calculated by determining the 
compound concentrations in the buffer and matrix compartments after dialysis as follows: %fu 
= 100 * buffer conc after dialysis / matrix conc after dialysis. The device recovery is checked 
by measuring the compound concentrations in the matrix before dialysis and calculating the 
percent recovery (mass balance). The recovery must be within 80% to 120% for data 
acceptance. P-glycoprotein assay. P-glycoprotein (permeability-glycoprotein, abbreviated 
as “P-gp” also known as multidrug resistance protein 1 (MDR1) is the most studied and best 
characterized drug transporter78. The P-gp assay evaluates the ability of test compounds to 
serve as a P-gp substrate. 
Plasmids. Synthesis of CB2, vasopressin V2 receptor (V2R), TwinStrep and 1D4 tags was 
ordered (Genewiz). CB1 gene was from Addgene. SNAP‑tag comes from pSNAPf‑ADRβ2 
control plasmid (NEB, #N9184). SNAP‑CB2‑TwinStrep‑1D4, TwinStrep‑SNAP‑CB1 and 
TwinStrep‑SNAP‑V2R constructs (sequences in SI) were cloned into the multiple cloning site 
of the pcDNA4/TO vector from Invitrogen by PCR using the respective plasmids as templates, 
followed by fragment assembly using home‑made Gibson assembly mix79. CB2 single-residue 
mutants F87A, V113A, F183A and W194A were generated from wild-type 
SNAP‑CB2‑TwinStrep‑1D4  construct using two-fragment PCR approach with mutation-
containing primers, followed by Gibson assembly, as described earlier80. Plasmids encoding 
β‑arrestin1‑RlucII81, β‑arrestin2‑RlucII82, human GRK283, rGFP‑CAAX65, rGFP‑FYVE65, 
Gs‑RlucII67, Gβ164, Gγ2‑GFP1064, wild‑type G proteins (Gi1, Gi2, Gi3, GoA, GoB, Gz, Gq, G11, G14, 
G15, G12, G13) and effector proteins fused to RlucII (RabGAP‑RlucII, p63‑RlucII, p115‑RlucII, 
PDZ‑RhoGEF‑RlucII)66 were previously described. 
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For G protein activation assay, receptor and wild‑type Gα subunit were combined with an 
appropriate RlucII‑fused signaling effector (depending on Gα subunit) and rGFP‑fused CAAX 
domain (embedded in plasma membrane), monitoring increase in BRET signal upon 
recruitment of signaling effector to the plasma membrane as a result of G protein activation. 
An exemption is activation of Gs protein where receptor was combined with RlucII‑fused Gα 
subunit, wild‑type Gβ1, and GFP10‑fused Gγ2 subunit, monitoring decrease in BRET signal 
upon G protein heterotrimer dissociation. In β‑arrestin recruitment assay, receptor was 
combined with RlucII‑fused β‑arrestin, wild‑type GRK2, and rGFP‑fused CAAX domain 
(embedded in plasma membrane), monitoring increase of BRET signal upon β‑arrestin 
recruitment to the receptor in plasma membrane. In order to detect β‑arrestin trafficking to the 
endosomes upon receptor internalized, rGFP‑FYVE (embedded in endosomal membrane) 
was transfected instead of rGFP‑CAAX. 
Transfection. For all experiments human embryonic kidney (HEK) 293SL cells84 were used 
and regularly tested for mycoplasma contamination (PCR Mycoplasma Detection kit, ABM, 
Canada). HEK293SL cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM), 
4.5 g/L glucose, with L‑glutamine and phenol red, without sodium pyruvate (Wisent Inc., 
Canada), supplemented with 10% Newborn Calf Serum (heat‑inactivated; Wisent Inc., 
Canada) and 1x Penicillin‑Streptomycin (Wisent Inc., Canada) in adherent culture at 37°C and 
5% CO2. Cells were dissociated using 0.05% Trypsin with 0.53 mM EDTA (Wisent Inc., 
Canada) and transiently co‑transfected with receptor and biosensor DNA using 25 kDa linear 
polyethylenimin (PEI; Polysciences Inc., USA). PEI was dissolved in water as 1 mg/mL stock 
solution with pH of 6.5–7.5 and kept at -20°C. Once thawed, aliquots were not refrozen. For 
the transfection, PEI was diluted to 0.03 mg/mL with sterile PBS: 30 μg PEI in 100 μL total 
volume for a condition. It was vortexed and incubated at RT for 10 min. DNA was mixed and 
diluted to 0.01 mg/mL with PBS: 1 μg DNA per 100 μL total volume for a condition. If less than 
1 μg receptor/biosensor DNA was needed per condition, it was topped up by sheared salmon 
sperm DNA (Invitrogen – Life Technologies Inc., Canada). Detailed amounts of DNA used for 
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each biosensor can be found in Table S4, Table S5 and Table S6. Diluted DNA and PEI were 
combined 1:1 (100 μL + 100 μL), vortexed, and incubated at RT for 20 min. The mixture was 
added to a suspension of 240’000 HEK293SL cells in 1.2 mL of the cell growth medium, 
followed by the distribution into Cellstar® PS 96‑well cell culture plates (Greiner Bio‑One, 
Germany) at a density of 20’000 cells per well and incubation at 37°C, 5% CO2. The 
transfection protocol is illustrated in Figure S5. For experiments with CB2 mutants, HEK293SL 
cells were transfected in Dulbecco’s Modified Eagle’s Medium (DMEM), 4.5 g/L glucose, with 
L‑glutamine, without phenol red and sodium pyruvate (Wisent Inc., Canada), supplemented 
with 10% Newborn Calf Serum (heat‑inactivated; Wisent Inc., Canada) and 1x 
Penicillin‑Streptomycin (Wisent Inc., Canada). 
BRET experiments. Coelenterazine 400a (Prolume Ltd., USA) was used as the luciferase 
substrate. It was solubilized as 1 mM stock solution in anhydrous ethanol and kept at -20°C. 
Ligands were solubilized in DMSO as 1, 10 or 50 mM stock solutions and kept at ‑20°C. BRET 
experiments are performed 2 days post‑transfection. Transfection medium was aspirated from 
wells, cells were washed with 200 μL PBS (Wisent Inc., Canada) and 100 μL Tyrode’s buffer 
was added (137 mM NaCl, 1 mM mgCl2, 1 mM CaCl2, 0.9 mM KCl, 3.6 mM NaH2PO4, 11.9 
mM NaHCO3, 25 mM HEPES, 5.55 mM ᴅ‑glucose, pH = 7.4). Plates were kept at 37°C for at 
least 30 min before the measurement. Just before the experiment, ligand dilutions in DMSO 
and DBC working solution were prepared (25 μM DBC and 1% Pluronic F127 (Sigma, Canada) 
in Tyrode’s buffer). For the experiment, one plate at a time was taken out of the incubator, 1 
μL of appropriate drug dilution in DMSO was added using an electronic multichannel pipette 
and mixed by moving the plate up‑down‑left‑right for 5 s before returning the plate in the 
incubator. Five minutes before a BRET measurement, 10 μL of DBC working solution was 
added (final 2.5 µM) and the plate was returned to the incubator. BRET measurements were 
performed on a Biotek Synergy Neo plate reader at room temperature 10 minutes (G protein) 
or 20 minutes (β‑arrestin) after ligand stimulation. RlucII signal was recorded using 410/80 nm 
filter, while rGFP signal was recorded using 515/30 nm filter, with the integration time of 0.4 s 
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and a gain of 150 for both channels, read height being 4.5 mm. The BRET measurement 
protocol is illustrated in Figure S5. For experiments with CB2 mutants, cells were not washed 
with PBS, but transfection medium was immediately replaced with 100 μL Tyrode’s buffer. 
Ligand was added in 0.4 μL of appropriate dilution in DMSO and 10 μL of DBC working solution 
was added using a Multidrop Combi (Thermo Scientific) and shaken for 10 seconds (final 5 
µM), followed by incubation at RT prior to BRET measurement. 
Cell surface ELISA measurements. Cell surface expression levels of CB2 mutants relative 
to the wild-type receptor were measured by ELISA as follows. HEK293SL cells were diluted 
to 200’000 cells/ml. For each receptor variant, 200 ng receptor plasmid were combined with 
800 ng salmon sperm DNA and PEI at a 1:3 ratio of DNA to PEI, followed by vortexing. After 
20 min incubation, 1.2 ml cells were added to each sample. The transfection mixture was 
plated into poly-D-lysine coated 96-well plates using 100 μl/well and four wells per condition. 
The cells were kept at 37°C 5% CO2 for 2 days. Each well was washed with 200 μl PBS and 
the cells were fixed with 50 μl 3% paraformaldehyde (PFA) per well for 10 min. The wells were 
washed three times with 100 μl/well washing buffer (PBS + 0.5% BSA), including last wash 
step with 10 min incubation period at RT. Per well, 50 μl of 0.25 μg/ml primary rabbit anti-
SNAP antibody (GenScript, USA) was added and incubated for 1 h at RT, followed by washing 
as above. Then, 50 μl of a 1:1000 dilution of anti-rabbit HRP antibody (GE Healthcare) was 
added per well, followed by incubation at RT for 1 h. The cells were washed with washing 
buffer as described above, followed by three 10 min wash steps with PBS. SigmaFast solution 
(100 μl) was added to cells, followed by incubation at RT protected from light until color change 
was observed. To stop the reaction, 25 μl of 3M HCl were added to each well and 100 μl of 
the solution were transferred to a new transparent 96-well plate for the measurement. The 
absorbance at 492 nm was measured using a Tecan GENios Plus microplate reader, reporting 
on the amount of receptor expressed. Cell-surface ELISAs were carried out in three biological 
replicates with technical quadruplicates. 
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Effect of the receptor expression level on maximal ligand‑induced response. Receptor 
titrations were performed to test how Emax for each pathway/ligand changes with the amount 
of expressed wild‑type CB2. Various amounts of CB2 DNA were transfected (0, 0.1, 0.5, 1, 
2.5, 5, 10, 25, 50, 100, 150, 200% of the amount used for each biosensor), together with other 
biosensor components and the appropriate amount of ssDNA (to have 1 μg DNA in total) in 
duplicates. Two days post‑transfection one replicate was used to perform ELISA, while the 
other replicate was used to measure BRET signal upon stimulation with 1 μM HU210 ligand, 
as described above. Change in BRET (ΔBRET) vs. amount of CB2 transfected (percentage 
of the amount used for each biosensor), and cell‑surface expression level (determined by 
ELISA) vs. amount of CB2 transfected were measured. Correlation of ΔBRET and 
ELISA‑measured expression was determined, and data fit equation parameters (linear 
regression or non-linear hyperbolic fit) were used to correct ΔBRET output of each mutant for 
its previously measured expression level. 
Data analysis. Ligand screen experiments were performed as three independent experiments 
in technical triplicates (CB1) or quadruplicates (CB2). Experiments with CB2 mutants were 
performed as three independent experiments, but without technical replicates. Nonlinear 
regression analysis of the concentration‑response curves was done with GraphPad Prism 
7.03 for Windows (GraphPad Software, USA). Concentration‑response data were fitted into 
“Sigmoidal dose‑response” (Hill Slope was constrained to 1) and are reported as mean ± 
standard error of mean (SE). For each pathway ligand‑induced responses were normalized to 
WIN55212‑2 for the given pathway, to allow comparison of ligand effects across different 
biosensors. In order to calculate bias factors, data were fitted into the equation for operational 
model of biased agonism and analyzed as described in van der Westhuizen et al.68, using 
WIN55252‑2 as a reference compound in all the pathways, and results are reported as mean 
± standard error of mean (SE). Bar charts and concentration‑response charts were plotted 
using GraphPad Prism. 
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Selection of CB2 mutants using Arpeggio. A CB2 homology model with HU210 ligand was 
generated with MOE (Molecular Operating Environment (MOE) 2019.01; Chemical Computing 
Group ULC, Montreal, Canada) applying default settings. The template was the active CB1 
structure with bound THC (5XR8). Arpeggio server69 
(http://biosig.unimelb.edu.au/arpeggioweb/) was used to analyze contacts formed between 
the ligand and receptor, selecting the residues that make the largest number of "specific” types 
of atom-atom interactions (F87, F94, F183, W194 and F281, Figure S2) such as π‒π stacking, 
hydrophobic‒van der Waals and weak polar‒van der Waals interactions. The selected 
residues were mutated into alanines one at a time, as described above. 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.09.375162doi: bioRxiv preprint 
